<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">59018</article-id><article-id pub-id-type="doi">10.7554/eLife.59018</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Microbiology and Infectious Disease</subject></subj-group><subj-group subj-group-type="heading"><subject>Structural Biology and Molecular Biophysics</subject></subj-group></article-categories><title-group><article-title>Structural ordering of the <italic>Plasmodium berghei</italic> circumsporozoite protein repeats by inhibitory antibody 3D11</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-190514"><name><surname>Kucharska</surname><given-names>Iga</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-6150-3419</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund10"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-190513"><name><surname>Thai</surname><given-names>Elaine</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-7576-154X</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-190515"><name><surname>Srivastava</surname><given-names>Ananya</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-179735"><name><surname>Rubinstein</surname><given-names>John L</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-0566-2209</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund7"/><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-40981"><name><surname>Pomès</surname><given-names>Régis</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-3068-9833</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-126745"><name><surname>Julien</surname><given-names>Jean-Philippe</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-7602-3995</contrib-id><email>jean-philippe.julien@sickkids.ca</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund7"/><xref ref-type="other" rid="fund9"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution>Program in Molecular Medicine, The Hospital for Sick Children Research Institute</institution><addr-line><named-content content-type="city">Toronto</named-content></addr-line><country>Canada</country></aff><aff id="aff2"><label>2</label><institution>Department of Biochemistry, University of Toronto</institution><addr-line><named-content content-type="city">Toronto</named-content></addr-line><country>Canada</country></aff><aff id="aff3"><label>3</label><institution>Department of Medical Biophysics, University of Toronto</institution><addr-line><named-content content-type="city">Toronto</named-content></addr-line><country>Canada</country></aff><aff id="aff4"><label>4</label><institution>Department of Immunology, University of Toronto</institution><addr-line><named-content content-type="city">Toronto</named-content></addr-line><country>Canada</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Faraldo-Gómez</surname><given-names>José D</given-names></name><role>Reviewing Editor</role><aff><institution>National Heart, Lung and Blood Institute, National Institutes of Health</institution><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Faraldo-Gómez</surname><given-names>José D</given-names></name><role>Senior Editor</role><aff><institution>National Heart, Lung and Blood Institute, National Institutes of Health</institution><country>United States</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date date-type="publication" publication-format="electronic"><day>30</day><month>11</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>9</volume><elocation-id>e59018</elocation-id><history><date date-type="received" iso-8601-date="2020-05-17"><day>17</day><month>05</month><year>2020</year></date><date date-type="accepted" iso-8601-date="2020-11-04"><day>04</day><month>11</month><year>2020</year></date></history><permissions><copyright-statement>© 2020, Kucharska et al</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Kucharska et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-59018-v1.pdf"/><abstract><p>Plasmodium sporozoites express circumsporozoite protein (CSP) on their surface, an essential protein that contains central repeating motifs. Antibodies targeting this region can neutralize infection, and the partial efficacy of RTS,S/AS01 – the leading malaria vaccine against <italic>P. falciparum</italic> (Pf) – has been associated with the humoral response against the repeats. Although structural details of antibody recognition of PfCSP have recently emerged, the molecular basis of antibody-mediated inhibition of other Plasmodium species via CSP binding remains unclear. Here, we analyze the structure and molecular interactions of potent monoclonal antibody (mAb) 3D11 binding to <italic>P. berghei</italic> CSP (PbCSP) using molecular dynamics simulations, X-ray crystallography, and cryoEM. We reveal that mAb 3D11 can accommodate all subtle variances of the PbCSP repeating motifs, and, upon binding, induces structural ordering of PbCSP through homotypic interactions. Together, our findings uncover common mechanisms of antibody evolution in mammals against the CSP repeats of Plasmodium sporozoites.</p></abstract><abstract abstract-type="executive-summary"><title>eLife digest</title><p>Malaria is a significant health concern, killing about 400,000 people each year. While antimalarial drugs and insecticides have successfully reduced deaths over the last 20 years, the parasite that causes malaria is starting to gain resistance to these treatments. Vaccines offer an alternative route to preventing the disease. However, the most advanced vaccine currently available provides less than 50% protection.</p><p>Vaccines work by encouraging the body to develop proteins called antibodies, which can recognize the parasite and trigger an immune response that blocks the infection. These antibodies target a molecule on the parasite’s surface called circumsporozoite protein, or CSP for short. Therefore, having a better understanding of how antibodies interact with CSP could help researchers design more effective treatments.</p><p>A lot of what is known about malaria has come from studying this disease in mice. However, it remained unclear whether antibodies produced in rodents combat the malaria-causing parasite in a similar manner to human antibodies. To answer this question, Kucharska, Thai et al. studied a mouse antibody called 3D11, which targets CSP on the surface of a parasite that causes malaria in rodents. The interaction between CSP and 3D11 was studied using three different techniques in order to better understand how the structure of CSP changes when bound by antibodies.</p><p>The experiments showed that although CSP has a highly flexible structure, it forms a more stable, spiral-like architecture when bound to multiple copies of 3D11. A similar type of assembly was previously observed in studies investigating how CSP interacts with human antibodies. Further investigation revealed that the molecular connections between 3D11 and CSP share a lot of similarities with how human antibodies recognize CSP.</p><p>These findings reveal how mammals evolved similar mechanisms for detecting and inhibiting malaria-causing parasites. This highlights the robust features antibodies need to launch an immune response against malaria, which could help develop a more effective vaccine.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>antibody</kwd><kwd><italic>Plasmodium berghei</italic></kwd><kwd>molecular biology</kwd><kwd>Circumsporozoite protein</kwd><kwd>structural biology</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100007631</institution-id><institution>Canadian Institute for Advanced Research</institution></institution-wrap></funding-source><award-id>Azrieli Global Scholar program</award-id><principal-award-recipient><name><surname>Julien</surname><given-names>Jean-Philippe</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution>Ontario Ministry of Economic Development, Job Creation and Trade</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Rubinstein</surname><given-names>John L</given-names></name><name><surname>Julien</surname><given-names>Jean-Philippe</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001804</institution-id><institution>Canada Research Chairs</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Rubinstein</surname><given-names>John L</given-names></name><name><surname>Julien</surname><given-names>Jean-Philippe</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000024</institution-id><institution>Canadian Institutes of Health Research</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Pomès</surname><given-names>Régis</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000024</institution-id><institution>Canadian Institutes of Health Research</institution></institution-wrap></funding-source><award-id>Canada Graduate Scholarship</award-id><principal-award-recipient><name><surname>Thai</surname><given-names>Elaine</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000038</institution-id><institution>Natural Sciences and Engineering Research Council of Canada</institution></institution-wrap></funding-source><award-id>Canada Graduate Scholarship</award-id><principal-award-recipient><name><surname>Srivastava</surname><given-names>Ananya</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000196</institution-id><institution>Canada Foundation for Innovation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Rubinstein</surname><given-names>John L</given-names></name><name><surname>Julien</surname><given-names>Jean-Philippe</given-names></name></principal-award-recipient></award-group><award-group id="fund9"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100012171</institution-id><institution>Ontario Research Foundation</institution></institution-wrap></funding-source><award-id>Early ResearcherAward program</award-id><principal-award-recipient><name><surname>Julien</surname><given-names>Jean-Philippe</given-names></name></principal-award-recipient></award-group><award-group id="fund10"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000165</institution-id><institution>Sick Kids Foundation</institution></institution-wrap></funding-source><award-id>Restracomp Fellowship</award-id><principal-award-recipient><name><surname>Kucharska</surname><given-names>Iga</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>A comprehensive structural analysis of inhibitory murine antibody 3D11 binding to <italic>Plasmodium berghei</italic> circumsporozoite protein reveals common mechanisms of antibody evolution in mammals against Plasmodium parasites.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Despite extensive biomedical and public health measures, malaria persists as a major global health concern, with an estimated 405,000 deaths and 228 million cases annually (<xref ref-type="bibr" rid="bib94">WHO, 2019</xref>). Moreover, resistant strains have been detected against all currently available antimalarial drugs, including sulfadoxine/pyrimethamine, mefloquine, halofantrine, quinine, and artemisinin (<xref ref-type="bibr" rid="bib13">Cui et al., 2015</xref>; <xref ref-type="bibr" rid="bib77">Ross and Fidock, 2019</xref>). Although ~94% of deaths are caused by <italic>Plasmodium falciparum</italic> (Pf) (<xref ref-type="bibr" rid="bib94">WHO, 2019</xref>), other Plasmodium species that infect humans (<italic>P. vivax, P. malariae, P. knowlesi</italic> and <italic>P. ovale</italic>) also cause debilitating disease and have been associated with fatal outcomes (<xref ref-type="bibr" rid="bib45">Lover et al., 2018</xref>). All Plasmodium species have a complex life cycle divided between a vertebrate host and an <italic>Anopheles</italic> mosquito vector (<xref ref-type="bibr" rid="bib30">Hall and Fauci, 2009</xref>). During a blood meal, sporozoites are deposited into the skin of a host organism from the salivary glands of a mosquito, and subsequently migrate through the bloodstream to infect host hepatocytes (<xref ref-type="bibr" rid="bib18">de Koning-Ward et al., 2015</xref>). Due to the small number of parasites transmitted and the expression of protein antigens that possess conserved functional regions (<xref ref-type="bibr" rid="bib76">Rosenberg et al., 1990</xref>; <xref ref-type="bibr" rid="bib87">Smith et al., 2014</xref>), the pre-erythrocytic sporozoite stage of the Plasmodium life cycle has long been considered a promising target for the development of an anti-malarial vaccine (<xref ref-type="bibr" rid="bib58">Nussenzweig and Nussenzweig, 1984</xref>).</p><p>Circumsporozoite protein (CSP) is the most abundant protein on the surface of Plasmodium sporozoites, and is necessary for parasite development in mosquitoes and establishment of infection in host liver cells (<xref ref-type="bibr" rid="bib9">Cerami et al., 1992</xref>; <xref ref-type="bibr" rid="bib27">Frevert et al., 1993</xref>; <xref ref-type="bibr" rid="bib51">Ménard et al., 1997</xref>). Flanked by N- and C-terminal domains, CSP contains an unusual central region consisting of multiple, short (4 to 8) amino acid (aa) repeats (<xref ref-type="bibr" rid="bib24">Eichinger et al., 1986</xref>; <xref ref-type="bibr" rid="bib14">Dame et al., 1984</xref>; <xref ref-type="bibr" rid="bib67">Plassmeyer et al., 2009</xref>; <xref ref-type="bibr" rid="bib96">Zavala et al., 1983</xref>). The sequence of the repeating motif depends on the Plasmodium species and field isolate (<xref ref-type="bibr" rid="bib11">Chenet et al., 2012</xref>; <xref ref-type="bibr" rid="bib74">Rich et al., 2000</xref>; <xref ref-type="bibr" rid="bib89">Tahar et al., 1998</xref>). Importantly, the central region of CSP is highly immunodominant and antibodies targeting the repeats can inhibit sporozoite infectivity by preventing parasite migration (<xref ref-type="bibr" rid="bib53">Mishra et al., 2012</xref>) and attachment to hepatocytes (<xref ref-type="bibr" rid="bib69">Potocnjak et al., 1980</xref>; <xref ref-type="bibr" rid="bib95">Yoshida et al., 1980</xref>). PfCSP is a major component of the leading malaria vaccine RTS,S/AS01, which is currently undergoing pilot implementation in Africa (<xref ref-type="bibr" rid="bib3">Adepoju, 2019</xref>; <xref ref-type="bibr" rid="bib22">Draper et al., 2018</xref>). Anti-PfCSP repeat antibodies have been suggested to form the predominant humoral immune response elicited by RTS,S/AS01, and correlate with vaccine efficacy (<xref ref-type="bibr" rid="bib20">Dobaño et al., 2019</xref>; <xref ref-type="bibr" rid="bib49">McCall et al., 2018</xref>; <xref ref-type="bibr" rid="bib59">Olotu et al., 2016</xref>). However, RTS,S/AS01 offers only modest and short-lived protection (<xref ref-type="bibr" rid="bib81">RTS,S Clinical Trials Partnership, 2015</xref>; <xref ref-type="bibr" rid="bib80">RTS,S Clinical Trials Partnership et al., 2012</xref>; <xref ref-type="bibr" rid="bib79">RTS,S Clinical Trials Partnership et al., 2011</xref>); thus, it is critical to develop a better molecular understanding of the antibody response against this Plasmodium antigen, particularly the repeat region (<xref ref-type="bibr" rid="bib16">Davies et al., 2015</xref>; <xref ref-type="bibr" rid="bib21">Doolan, 2011</xref>; <xref ref-type="bibr" rid="bib37">Illingworth et al., 2019</xref>), to obtain valuable information needed for improved vaccine design.</p><p>Our understanding of Plasmodium biology and key host-parasite interactions has been enhanced by studies using rodent parasites, including <italic>P. berghei</italic> (Pb), <italic>P. chabaudi</italic> and <italic>P. yoelii</italic> (<xref ref-type="bibr" rid="bib19">De Niz and Heussler, 2018</xref>). In vivo studies evaluating the inhibitory potential of mAbs are often derived from these rodent parasite models, or transgenic rodent sporozoites harboring PfCSP, as Pf fails to infect rodents. For example, mAb 3D11 was isolated from mice exposed to the bites of mosquitoes that had been infected with γ-irradiated Pb parasites (<xref ref-type="bibr" rid="bib95">Yoshida et al., 1980</xref>). mAb 3D11 recognition of the PbCSP central repeat region on the surface of live sporozoites resulted in abolished Pb infectivity in vitro and in vivo (<xref ref-type="bibr" rid="bib12">Cochrane et al., 1976</xref>). Electron micrographs of Pb sporozoites pre-treated with mAb 3D11 revealed the presence of amorphous, precipitated material on the parasite surface characteristic of the circumsporozoite precipitation reaction (<xref ref-type="bibr" rid="bib95">Yoshida et al., 1980</xref>). This antibody continues to be widely used in model systems of sporozoite infection. For example, a recent study used mAb 3D11 in combination with transmission-blocking mAb 4B7 to show that antibody targeting of both the pre-erythrocytic and sexual stages of a Pfs25-transgenic Pb parasite led to a synergistic reduction of parasite transmission in mice (<xref ref-type="bibr" rid="bib86">Sherrard-Smith et al., 2018</xref>). However, it remains unclear whether murine mAb 3D11 recognizes the central domain of PbCSP with the same molecular principles as the most potent human anti-PfCSP repeat antibodies, for which molecular details have recently emerged (<xref ref-type="bibr" rid="bib38">Imkeller et al., 2018</xref>; <xref ref-type="bibr" rid="bib40">Julien and Wardemann, 2019</xref>; <xref ref-type="bibr" rid="bib42">Kisalu et al., 2018</xref>; <xref ref-type="bibr" rid="bib56">Murugan et al., 2020</xref>; <xref ref-type="bibr" rid="bib61">Oyen et al., 2018</xref>; <xref ref-type="bibr" rid="bib60">Oyen et al., 2017</xref>; <xref ref-type="bibr" rid="bib91">Tan et al., 2018</xref>; <xref ref-type="bibr" rid="bib93">Triller et al., 2017</xref>).</p><p>Here, we characterized the structure of the PbCSP repeats unliganded and as recognized by mAb 3D11. Our molecular studies reveal that mAb 3D11 binds across all PbCSP repeat motifs and induces structural ordering of PbCSP in a spiral-like conformation using homotypic interactions.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Repeat motifs of PfCSP and PbCSP have similar structural propensities</title><p>The central repeats of PfCSP and PbCSP consist of recurring 4-aa motifs rich in asparagine and proline residues (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). PfCSP is composed of repeating NANP motifs interspersed with intermittent NVDP repeats, and a singular NPDP motif in the junction immediately following the N-terminal domain. While the major repeat motif of PfCSP is often referred to as NANP, numerous reports have identified NPNA as the structurally relevant unit of the central region (<xref ref-type="bibr" rid="bib42">Kisalu et al., 2018</xref>; <xref ref-type="bibr" rid="bib60">Oyen et al., 2017</xref>; <xref ref-type="bibr" rid="bib23">Dyson et al., 1990</xref>; <xref ref-type="bibr" rid="bib28">Ghasparian et al., 2006</xref>). Similarly, the central domain of PbCSP contains an array of PPPP and PAPP motifs interspersed with NPND or NAND motifs (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). Notably, both orthologs contain the conserved pentamer, KLKQP, known as Region I, at the C-terminal end of the N-terminal domain.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Comparison of PfCSP and PbCSP repeat sequences and structures.</title><p>(<bold>A</bold>) Schematic representations of PfCSP strain NF54 and PbCSP strain ANKA, each comprising an N-terminal domain, central repeat region, and C-terminal domain. The junctional region (J) immediately following the N-terminal domain of PfCSP is indicated. Colored bars represent each repeat motif. The sequences of each CSP central repeat region and corresponding peptides used in the study are shown below their respective schematics. (<bold>B-G</bold>) Conformational ensembles of CSP peptides in solution from molecular dynamics simulations. (<bold>B</bold>) Superposition of the conformations of the four PfCSP-derived peptides at each nanosecond. The peptides are aligned to the conformational median structure and only the backbone is shown for clarity. (<bold>C</bold>) Ensemble-averaged backbone-backbone hydrogen-bonding maps for each PfCSP peptide sequence. The propensity for hydrogen bonds between the NH groups (y-axis) and CO groups (x-axis) is indicated by the color scale on the right. (<bold>D</bold>) Sample molecular dynamics snapshots of the highest-propensity turn for each PfCSP peptide are shown as sticks with hydrogen bonds shown as gray lines. The highest-propensity turn for each peptide is indicated by the arrowhead on the corresponding hydrogen-bonding map. (<bold>E</bold>) Superposition of the conformations of the four PbCSP-derived peptides at each nanosecond. The peptides are aligned to the conformational median structure and only the backbone is shown for clarity. (<bold>F</bold>) Ensemble-averaged backbone-backbone hydrogen-bonding maps for each PbCSP peptide sequence. The propensity for hydrogen bonds between the NH groups (y-axis) and CO groups (x-axis) is indicated by the color scale on the right. (<bold>G</bold>) Sample molecular dynamics snapshots of the highest-propensity turn for each PbCSP peptide are shown as sticks with hydrogen bonds shown as gray lines. The highest-propensity turn for each peptide is indicated by the arrowhead on the corresponding hydrogen-bonding map.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-59018-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Ensemble-averaged hydrogen-bonding propensities for PfCSP- and PbCSP-derived peptides.</title><p>(<bold>A</bold>) The propensity for hydrogen bonds between the NH groups of the backbone (y-axis) and CO groups of the side chains (x-axis) is indicated by the color scale on the right. (<bold>B</bold>) The propensity for hydrogen bonds between the NH groups of the side chains (y-axis) and CO groups of the backbone (x-axis) is indicated by the color scale on the right. (<bold>C</bold>) The propensity for hydrogen bonds between the NH groups of the side chains (y-axis) and CO groups of the side chains (x-axis) is indicated by the color scale on the right.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-59018-fig1-figsupp1-v1.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Experimental details of MD simulations.</title><p>(<bold>A</bold>) Time evolution of the radius of gyration of the different peptides from MD simulations. Shading represents the standard error of the mean computed from the different simulation repeats (see Materials and methods). The simulations are statistically converged after 100 ns. The average radius of gyration for each peptide is reported on the right. The individual peptides have been shifted on the y-axis to allow for ease of visualization. (<bold>B</bold>) The simulated propensity of having a specific hydrogen bond is shown on the diagonal, with the propensity of two specific hydrogen bonds (P(A∩B)) shown above the diagonal. Each individual NPNA motif is labelled from I-V. The difference of the simulated values from the calculated values (P(A)·P(B)) is shown below the diagonal. These differences are all well below the average standard error of mean of 0.04, confirming that the individual motifs are uncorrelated. (<bold>C</bold>) A mathematical example showing that the β-turn and pseudo β-turn propensities are independent and uncorrelated (P(A∩B)=P(A)·P(B)). This holds true for all the simulated peptides.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-59018-fig1-figsupp2-v1.tif"/></fig></fig-group><p>To examine and compare the structural properties of the various Pf and Pb repeat motifs in solution, we performed molecular dynamics (MD) simulations using eight different peptides ranging in length from 15 to 20 aa, with four peptides derived from Pf [KQPADGNPDPNANPN (‘KQPA’); NPDPNANPNVDPNANP (‘NPDP’); (NVDPNANP)<sub>2</sub>NVDP (‘NVDP’); and (NPNA)<sub>5</sub> (‘NPNA’)], and four peptides from Pb [(PPPPNPND)<sub>2</sub> (‘NPND’); (PPPPNAND)<sub>2</sub> (‘NAND’); (PAPPNAND)<sub>2</sub> (‘PAPP’); and PPPPNPNDPAPPNANAD (‘Mixed’); <xref ref-type="fig" rid="fig1">Figure 1B–G</xref>]. Each simulation was conducted in water for a total production time of 18 μs. All eight peptides were highly disordered and adopted a large ensemble of conformations with low to moderate secondary structure propensities (<xref ref-type="fig" rid="fig1">Figure 1B and E</xref>), which are best described in statistical terms. The only secondary structure observed was local, and consisted of sparse, transient hydrogen-bonded turns (<xref ref-type="fig" rid="fig1">Figure 1C and F</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref> and <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>, and <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). In particular, these interactions consisted of forward α-, β-, and γ-turns, with the β-turns being the most populated (up to 40%; <xref ref-type="fig" rid="fig1">Figure 1C and F</xref>), consistent with previous NMR studies focused on the NANP repeats (<xref ref-type="bibr" rid="bib23">Dyson et al., 1990</xref>). Across all peptides, the average β-turn lifetime ranged from 2.7 ± 0.2 ns for the Pb PPNA turn to 4.4 ± 0.4 ns for DPNA turns found within PfCSP (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>).</p><p>In line with reports identifying NPNA as the main structural repeating unit of PfCSP (<xref ref-type="bibr" rid="bib42">Kisalu et al., 2018</xref>; <xref ref-type="bibr" rid="bib60">Oyen et al., 2017</xref>; <xref ref-type="bibr" rid="bib23">Dyson et al., 1990</xref>; <xref ref-type="bibr" rid="bib28">Ghasparian et al., 2006</xref>), turns were predominantly observed within these motifs, as well as DPNA, NPNV, and ADGN sequences amongst the PfCSP peptides. NPND and PPNA exhibited the greatest propensity to form β-turns of the PbCSP repeats. Importantly, each individual motif consistently exhibited the same structural tendencies, independent of their position and the overall peptide sequence in which they were contained (<xref ref-type="fig" rid="fig1">Figure 1C and F</xref>, and <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). Furthermore, using the probability rule stating that two events are independent if the equation P(A∩B)=P(A)·P(B) holds true, we show that the presence of an intramolecular hydrogen bond in one motif does not alter the hydrogen-bonding propensities of adjacent motifs (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2B and C</xref>). Therefore, in both PfCSP and PbCSP we conclude that there is no discernable cooperativity between the structures of different repeat motifs, and as such, in the absence of extended or nonlocal secondary structure, each of these motifs behaves as an independent unit with its own intrinsic secondary structure propensities.</p><p>To examine the influence of Asn, Asp, and Gln sidechains on the conformational ensemble of the peptides, we computed contact maps for backbone-sidechain hydrogen bonds (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref> and <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). We found that the majority of contacts are in the form of pseudo α-turns and β-turns, with backbone NH groups donating to sidechain O atoms. Notably, we discovered that these transient sidechain contacts do not have a stabilizing effect on backbone-backbone hydrogen bonds and consequently, are not correlated with the presence of these bonds (numerical example in <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2B and C</xref>).</p><p>In summary, the four Pf and four Pb peptides corresponding to CSP central repeats were all found to be highly disordered, resulting in an ensemble of conformations. The only secondary structure elements present were sparse and local hydrogen-bonded turns within each motif. Each structural motif acted independently from adjacent sequences and behaved similarly in various peptides.</p></sec><sec id="s2-2"><title>Multiple copies of mAb 3D11 bind PbCSP with high affinity</title><p>Next, we investigated the binding of mAb 3D11 to the PbCSP repeat of low structural propensity. Our biolayer interferometry (BLI) studies indicated that 3D11 Fab binds PbCSP with complex kinetics, but overall high affinity (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). Isothermal titration calorimetry (ITC) also indicated a high affinity interaction, with a K<sub>D</sub> value of 159 ± 47 nM (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). In addition, ITC revealed a very high binding stoichiometry (N = 10 ± 1), suggesting that approximately ten copies of 3D11 Fab bound one molecule of PbCSP simultaneously. Size-exclusion chromatography coupled with multi-angle light scattering (SEC-MALS) characterization of the 3D11 Fab-PbCSP complex confirmed the high binding stoichiometry with a molecular weight of 587 ± 7 kDa for the complex (<xref ref-type="fig" rid="fig2">Figure 2C–D</xref>). This size is consistent with approximately eleven 3D11 Fabs bound to one molecule of PbCSP, and thus, is in agreement with the results from the ITC studies within experimental error. Therefore, through a number of biophysical studies, we show that up to eleven copies of 3D11 Fab can bind simultaneously to PbCSP with high affinity.</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Biophysical characterization of 3D11 Fab-PbCSP binding.</title><p>(<bold>A</bold>) Binding kinetics of twofold dilutions of 3D11 Fab to PbCSP. Representative sensorgrams are shown in black and 2:1 model best fits in red. Data are representative of three independent measurements. (<bold>B</bold>) Isothermal titration calorimetry (ITC) analysis of 3D11 Fab binding to PfCSP at 37°C. Above, raw data of PbCSP (0.005 mM) in the sample cell titrated with 3D11 Fab (0.4 mM). Below, plot and trendline of heat of injectant corresponding to the raw data. K<sub>D</sub> and N values resulting from three independent experiments are indicated. Standard error values are reported as standard error of the mean (SEM). (<bold>C</bold>) Results from size-exclusion chromatography coupled with multi-angle light scattering (SEC-MALS) for the 3D11 Fab-PbCSP complex. A representative measurement of the molar mass of the 3D11 Fab-PbCSP complex is shown as the red line. Mean molar mass and standard deviation are as indicated. (<bold>D</bold>) SDS-PAGE analysis of resulting Peaks 1 and 2 from SEC-MALS. Each peak was sampled in reducing and non-reducing conditions as indicated by + and -, respectively.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-59018-fig2-v1.tif"/></fig></sec><sec id="s2-3"><title>mAb 3D11 is cross-reactive with subtly different PbCSP motifs in the central repeat</title><p>We next sought to define the exact mAb 3D11 epitope. We first conducted BLI studies to confirm that mAb 3D11 does not bind the PbCSP C-terminal domain (residues 202–318; <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>). Next, we performed ITC studies to evaluate 3D11 Fab binding to each of the four peptides derived from the PbCSP central repeat region that were used in our MD simulations (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). Our experiments revealed that mAb 3D11 preferentially binds the NPND and Mixed peptides with high affinity (K<sub>D</sub> = 45 ± 15 nM and 44 ± 4 nM, respectively), but also binds the NAND and PAPP peptides, albeit with lower affinity (K<sub>D</sub> = 207 ± 1 nM and 611 ± 139 nM, respectively).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>3D11 Fab binding to PbCSP repeat peptides.</title><p>(<bold>A</bold>) Affinities of 3D11 Fab for PAPP, NAND, NPND, and Mixed peptides as measured by ITC. Symbols represent independent measurements. Mean K<sub>D</sub> values are shown above the corresponding bar. Error bars represent SEM. Peptide sequences are as indicated to the right of the plot, with variable residues underlined and shaded residues indicating those resolved in the corresponding X-ray crystal structures. (<bold>B</bold>) The 3D11 Fab binds the PAPP (pink), NAND (purple), NPND (blue) and Mixed (red) peptides in nearly identical conformations. mAb 3D11 CDRs are indicated. (<bold>C</bold>) Overview and side view of the NAND peptide (purple) in the binding groove of the 3D11 Fab shown as surface representation (H-chain shown in black and K-chain shown in gray). (<bold>D</bold>) Van der Waals interactions formed by side chain atoms of both Ala and Pro residues are indicated by orange dashed lines, and those unique to Pro6 and Pro10 are indicated by green dashed lines.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-59018-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Experimental details of mAb 3D11 binding.</title><p>(<bold>A</bold>) 3D11 Fab binding to peptides representative of the PbCSP αTSR domain (residue 263–318; red) and the full C-terminal domain (residues 202–318; PbC-CSP; blue). PbCSP (residue 24–318) was used as a positive control (black). (<bold>B</bold>) Composite omit map electron density contoured at 1.0 sigma (blue mesh) around PbCSP peptides PAPP, NAND, NPND and Mixed in complex with the 3D11 Fab. (<bold>C</bold>) Slight differences in H-bonding at the N- and C-terminal ends of the PbCSP repeat peptides when bound to the 3D11 Fab in the crystal structures. PbCSP peptides are colored as in <xref ref-type="fig" rid="fig3">Figure 3</xref>. Antibody residues partaking in H-bonds are colored orange. mAb 3D11 HCDR2 is colored in black and KCDR2 in white.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-59018-fig3-figsupp1-v1.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title>Interactions between mAb 3D11 aromatic side chains and PbCSP peptides.</title><p>Interactions formed between PbCSP peptide residues and aromatic side chains of the 3D11 Fab HCDR (black) and KCDR (white). PbCSP peptides are colored as in <xref ref-type="fig" rid="fig3">Figure 3</xref>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-59018-fig3-figsupp2-v1.tif"/></fig></fig-group><p>To gain insight into the molecular basis of this preference, we solved the X-ray crystal structures of 3D11 Fab in complex with each peptide. The structure of the 3D11 Fab-NPND complex was determined at 2.30 Å resolution, while the structures of 3D11 Fab in complex with each of the other three peptides were all solved at ~1.60 Å resolution (<xref ref-type="table" rid="table1">Table 1</xref>). Interestingly, all four peptides adopted almost identical conformations when bound by 3D11 Fab (<xref ref-type="fig" rid="fig3">Figure 3B</xref> and <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>), fitting deep into the binding groove and forming a curved, U-shaped structure (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). Amongst all four peptides, the mAb 3D11 core epitope consisted of eight residues [PN(A/P)NDP(A/P)P] with an all-atom RMSD &lt;0.5 Å. Importantly, this shared recognition mode ideally positions aromatic side chains in the mAb 3D11 complementarity determining regions (CDRs) to form favorable pi-stacking and hydrophobic cage interactions around each PbCSP peptide (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref>). Indeed, the majority of these contacts are made with residues that are conserved between all four PbCSP repeat peptides, and thus, contribute to the cross-reactive binding profile of mAb 3D11.</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>X-ray crystallography data collection and refinement statistics.</title><p>Despite binding in nearly identical conformations, differences exist in the molecular details of 3D11 Fab binding to each peptide that provide key insights into mAb 3D11 recognition of PbCSP. Our crystal structures revealed that more van der Waals contacts were formed by a Pro residue in the PPPP and NPND motifs compared to an Ala at the same position in the PAPP and NAND motifs (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). Consequently, the epitopes of the NAND, NPND and Mixed peptides had a slightly greater buried surface area (BSA; 753, 762, and 765 Å<sup>2</sup>, respectively) than the PAPP peptide (743 Å<sup>2</sup>), which only consists of Ala-containing motifs (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>). In particular, Pro10 of the PPPP motif found in the NAND and NPND peptides forms more van der Waals interactions with antibody residues H.Asn33 and H.Tyr52 compared to Ala10 of the PAPP motif present in PAPP and Mixed peptides. Similarly, Pro6 of the NPND motif in the NPND and Mixed peptides makes additional interactions with antibody residue K.Leu50 that are not present for Ala6 of the NAND motif within the PAPP and NAND peptides (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>). These differences in interactions observed at the atomic level directly relate to the binding affinities measured by ITC, where the PbCSP peptides that bury more surface area in the 3D11 paratope have the highest binding affinities (<xref ref-type="fig" rid="fig3">Figure 3A</xref>).</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top"/><th valign="top">3D11-PAPP</th><th valign="top">3D11-NAND</th><th valign="top">3D11-NPND</th><th valign="top">3D11-Mixed</th></tr></thead><tbody><tr><td valign="top">Beamline</td><td valign="top">APS-23-ID-D</td><td valign="top">APS-23-ID-D</td><td valign="top">NSLS-II-17-ID-1</td><td valign="top">APS-23-ID-B</td></tr><tr><td valign="top">Wavelength (Å)</td><td valign="top">1.033170</td><td valign="top">1.033200</td><td valign="top">0.979329</td><td valign="top">1.033167</td></tr><tr><td valign="top">Space group</td><td valign="top">P3<sub>2</sub>21</td><td valign="top">P3<sub>2</sub>21</td><td valign="top">P3<sub>2</sub>21</td><td valign="top">P3<sub>2</sub>21</td></tr><tr><td valign="top">Cell dimensions</td><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top"/></tr><tr><td valign="top"><italic>a,b,c</italic> (Å)</td><td valign="top">59.3, 59.3, 233.5</td><td valign="top">59.7, 59.7, 234.9</td><td valign="top">59.9, 59.9, 235.0</td><td valign="top">60.3, 60.3, 233.7</td></tr><tr><td valign="top">α, β, γ (°)</td><td valign="top">90, 90, 120</td><td valign="top">90, 90, 120</td><td valign="top">90, 90, 120</td><td valign="top">90, 90, 120</td></tr><tr><td valign="top">Resolution (Å)<sup>*</sup></td><td valign="top">40.0–1.60 (1.70–1.60)</td><td valign="top">40.0–1.55 (1.65–1.55)</td><td valign="top">40.0–2.27 (2.37–2.27)</td><td valign="top">40.0–1.55 (1.65–1.55)</td></tr><tr><td valign="top">No. molecules in ASU</td><td valign="top">1</td><td valign="top">1</td><td valign="top">1</td><td valign="top">1</td></tr><tr><td valign="top">No. observations</td><td valign="top">1,210,903 (196,555)</td><td valign="top">684,564 (117,091)</td><td valign="top">450,057 (47,142)</td><td valign="top">1,423,235 (247,601)</td></tr><tr><td valign="top">No. unique observations</td><td valign="top">64,371 (10,497)</td><td valign="top">70,664 (11,753)</td><td valign="top">23,398 (2,556)</td><td valign="top">72,981 (12,222)</td></tr><tr><td valign="top">Multiplicity</td><td valign="top">18.8 (18.7)</td><td valign="top">9.5 (9.7)</td><td valign="top">19.1 (17.4)</td><td valign="top">19.5 (20.3)</td></tr><tr><td valign="top">R<sub>merge</sub> (%)<sup>†</sup></td><td valign="top">10.3 (84.7)</td><td valign="top">8.4 (80.1)</td><td valign="top">13.8 (57.1)</td><td valign="top">8.3 (78.0)</td></tr><tr><td valign="top">R<sub>pim</sub> (%)<sup>‡</sup></td><td valign="top">2.4 (20.1)</td><td valign="top">2.9 (26.5)</td><td valign="top">3.2 (13.5)</td><td valign="top">1.9 (17.6)</td></tr><tr><td valign="top">&lt;I/σ I&gt;</td><td valign="top">16.3 (1.5)</td><td valign="top">13.8 (1.5)</td><td valign="top">19.0 (4.1)</td><td valign="top">19.6 (1.7)</td></tr><tr><td valign="top">CC<sub>½</sub></td><td valign="top">99.9 (68.0)</td><td valign="top">99.9 (56.7)</td><td valign="top">99.9 (93.5)</td><td valign="top">99.9 (84.3)</td></tr><tr><td valign="top">Completeness (%)</td><td valign="top">99.9 (100.0)</td><td valign="top">98.3 (97.2)</td><td valign="top">99.3 (94.4)</td><td valign="top">100.0 (100.0)</td></tr><tr><td valign="top">Refinement Statistics</td><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top"/></tr><tr><td valign="top">Reflections used in refinement</td><td valign="top">64,275</td><td valign="top">70,660</td><td valign="top">23,327</td><td valign="top">72,843</td></tr><tr><td valign="top">Reflections used for R-free</td><td valign="top">1999</td><td valign="top">1986</td><td valign="top">1173</td><td valign="top">2000</td></tr><tr><td valign="top">Non-hydrogen atoms</td><td valign="top">3823</td><td valign="top">3915</td><td valign="top">3665</td><td valign="top">3858</td></tr><tr><td valign="top">Macromolecule</td><td valign="top">3411</td><td valign="top">3423</td><td valign="top">3382</td><td valign="top">3439</td></tr><tr><td valign="top">Water</td><td valign="top">384</td><td valign="top">380</td><td valign="top">259</td><td valign="top">359</td></tr><tr><td valign="top">Heteroatom</td><td valign="top">28</td><td valign="top">112</td><td valign="top">24</td><td valign="top">60</td></tr><tr><td valign="top">R<sub>work</sub><sup>§</sup>/R<sub>free</sub><sup>¶</sup></td><td valign="top">15.9/18.8</td><td valign="top">16.4/18.4</td><td valign="top">16.6/22.2</td><td valign="top">16.6/18.1</td></tr><tr><td valign="top">Rms deviations from ideality</td><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top"/></tr><tr><td valign="top">Bond lengths (Å)</td><td valign="top">0.016</td><td valign="top">0.010</td><td valign="top">0.006</td><td valign="top">0.011</td></tr><tr><td valign="top">Bond angle (°)</td><td valign="top">1.43</td><td valign="top">1.15</td><td valign="top">0.87</td><td valign="top">1.22</td></tr><tr><td valign="top">Ramachandran plot</td><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top"/></tr><tr><td valign="top">Favored regions (%)</td><td valign="top">98.9</td><td valign="top">98.0</td><td valign="top">97.7</td><td valign="top">98.2</td></tr><tr><td valign="top">Allowed regions (%)</td><td valign="top">1.1</td><td valign="top">2.0</td><td valign="top">2.3</td><td valign="top">1.8</td></tr><tr><td valign="top">B-factors (Å<sup>2</sup>)</td><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top"/></tr><tr><td valign="top">Wilson B-value</td><td valign="top">27.1</td><td valign="top">24.0</td><td valign="top">32.0</td><td valign="top">26.3</td></tr><tr><td valign="top">Average B-factors</td><td valign="top">35.0</td><td valign="top">31.4</td><td valign="top">35.2</td><td valign="top">31.2</td></tr><tr><td valign="top">Average macromolecule</td><td valign="top">33.6</td><td valign="top">29.4</td><td valign="top">34.8</td><td valign="top">29.7</td></tr><tr><td valign="top">Average heteroatom</td><td valign="top">54.4</td><td valign="top">54.8</td><td valign="top">54.4</td><td valign="top">57.6</td></tr><tr><td valign="top">Average water molecule</td><td valign="top">46.3</td><td valign="top">41.9</td><td valign="top">38.3</td><td valign="top">41.2</td></tr></tbody></table><table-wrap-foot><fn><p>* Values in parentheses refer to the highest resolution bin.</p><p>† R<sub>merge</sub> = Σhkl Σi | Ihkl, i - &lt; Ihkl &gt; | / Σhkl &lt; Ihkl &gt; .</p></fn><fn><p>‡ R<sub>pim</sub> = Σhkl [1/(N – 1)]1/2 Σi | Ihkl, i - &lt; Ihkl &gt; | / Σhkl &lt; Ihkl &gt; .</p><p>§ R<sub>work</sub> = (Σ | |Fo | − |Fc | |) / (Σ | |Fo |) - for all data except as indicated in footnote ¶.</p></fn><fn><p>¶ 5% of data were used for the R<sub>free</sub> calculation.</p></fn></table-wrap-foot></table-wrap><p>Despite binding in nearly identical conformations, differences exist in the molecular details of 3D11 Fab binding to each peptide that provide key insights into mAb 3D11 recognition of PbCSP. Our crystal structures revealed that more van der Waals contacts were formed by a Pro residue in the PPPP and NPND motifs compared to an Ala at the same position in the PAPP and NAND motifs (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). Consequently, the epitopes of the NAND, NPND and Mixed peptides had a slightly greater buried surface area (BSA; 753, 762, and 765 Å<sup>2</sup>, respectively) than the PAPP peptide (743 Å<sup>2</sup>), which only consists of Ala-containing motifs (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>). In particular, Pro10 of the PPPP motif found in the NAND and NPND peptides forms more van der Waals interactions with antibody residues H.Asn33 and H.Tyr52 compared to Ala10 of the PAPP motif present in PAPP and Mixed peptides. Similarly, Pro6 of the NPND motif in the NPND and Mixed peptides makes additional interactions with antibody residue K.Leu50 that are not present for Ala6 of the NAND motif within the PAPP and NAND peptides (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>). These differences in interactions observed at the atomic level directly relate to the binding affinities measured by ITC, where the PbCSP peptides that bury more surface area in the 3D11 paratope have the highest binding affinities (<xref ref-type="fig" rid="fig3">Figure 3A</xref>).</p></sec><sec id="s2-4"><title>3D11 binding stabilizes the central PbCSP repeat in a spiral-like conformation</title><p>To understand how mAb 3D11 recognizes full-length PbCSP, we performed cryoEM analysis on the SEC-purified 3D11 Fab-PbCSP complex (<xref ref-type="fig" rid="fig2">Figure 2D</xref>). A dataset of 165,747 3D11 Fab-PbCSP particle images was refined with no symmetry imposed, resulting in a 3.2 Å resolution reconstruction of 3D11 Fabs peripherally arranged around PbCSP with their variable domains clustered around a central density (<xref ref-type="fig" rid="fig4">Figure 4</xref>, <xref ref-type="table" rid="table2">Table 2</xref> , and <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref> and <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>). Although the low-pass filtered (20 Å) cryoEM map of the 3D11 Fab-PbCSP complex contains visible density for &gt;10 3D11 Fabs (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2F</xref>), only the density for the seven central Fabs was strong enough to warrant building a molecular model. Indeed, 3D Variability Analysis (<xref ref-type="bibr" rid="bib71">Punjani and Fleet, 2020</xref>) in cryoSPARC v2 (<xref ref-type="bibr" rid="bib70">Punjani et al., 2017</xref>) revealed continuous flexibility at the N- and C-termini of the 3D11 Fab-PbCSP complex (<xref ref-type="video" rid="fig4video1">Figure 4—video 1</xref>). The PbCSP repeat forms the core of the complex and is arranged into a triangular spiral of 51 Å pitch and 16 Å diameter (<xref ref-type="fig" rid="fig4">Figure 4B–C</xref>), which fits 61 of the 108 residues in the PbCSP central region. We assigned the density to the high-affinity PPPPNPND repeats.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Spiral organization of the PbCSP repeat upon 3D11 Fab binding.</title><p>(<bold>A</bold>) The cryoEM map of the 3D11 Fab-PbCSP complex reveals high-resolution information for seven predominant 3D11 Fabs. Regions corresponding to Fabs are colored from pink to gray. (<bold>B</bold>) CryoEM map of the 3D11 Fab-PbCSP complex is shown as a transparent light gray surface with the PbCSP region highlighted in black. (<bold>C</bold>) The PbCSP model built into the cryoEM map is shown in dark gray as sticks and aligned to the schematic representation of the PbCSP protein sequence.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-59018-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>CryoEM data processing workflow in cryoSPARC v2.</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-59018-fig4-figsupp1-v1.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>CryoEM analysis of the 3D11 Fab-PbCSP complex.</title><p>(<bold>A</bold>) Left panel – a representative cryoEM micrograph used to calculate the 3D11 Fab-PbCSP cryoEM map. Right panel – a cryoEM micrograph of the 3D11 Fab-PbCSP complex from a 200 kV screening microscope with individual particles highlighted with white circles. Scale bars: 50 nm. (<bold>B</bold>) Selected 2D class averages of the 3D11 Fab-PbCSP complex. (<bold>C</bold>) Particle orientation distribution plot. (<bold>D</bold>) Fourier shell correlation curve from the final 3D non-uniform refinement of the 3D11 Fab-PbCSP complex in cryoSPARC v2. (<bold>E</bold>) Local resolution (Å) plotted on the surface of the cryoEM map. (<bold>F</bold>) Low-pass filtered (20 Å) cryoEM map of the 3D11 Fab-PbCSP complex with observable 3D11 Fabs numbered. (<bold>G</bold>) CryoEM map of PbCSP (gray mesh) with the model shown as sticks (black carbons).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-59018-fig4-figsupp2-v1.tif"/></fig><fig id="fig4s3" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 3.</label><caption><title>Comparison between the 3D11 Fab-PbCSP cryoEM structure and 3D11 Fab-NPND peptide crystal structure.</title><p>(<bold>A</bold>) Color representation of the backbone RMSD of the 3D11 Fab variable region and PbCSP core epitope between the 3D11 Fab-PbCSP cryoEM structure and the 3D11 Fab-NPND peptide crystal structure. (<bold>B</bold>) Color representation of the all-atom RMSD of the 3D11 Fab residues engaging in Fab-Fab contacts between the 3D11 Fab-PbCSP cryoEM structure and the 3D11 Fab-NPND peptide crystal structure. RMSD values were calculated using PyMOL (<xref ref-type="bibr" rid="bib85">Schrodinger LLC, 2015</xref>) and plotted by color on the secondary structure of the 3D11 Fab-NPND peptide crystal structure.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-59018-fig4-figsupp3-v1.tif"/></fig><media id="fig4video1" mime-subtype="mp4" mimetype="video" xlink:href="elife-59018-fig4-video1.mp4"><label>Figure 4—video 1.</label><caption><title>3D Variability Analysis on 165,747 particle images of the 3D11 Fab-PbCSP complex.</title></caption></media></fig-group><table-wrap id="table2" position="float"><label>Table 2.</label><caption><title>CryoEM data collection and refinement statistics.</title></caption><table frame="hsides" rules="groups"><tbody><tr><th>Data collection</th><th/></tr><tr><td>Electron microscope</td><td>Titan Krios G3</td></tr><tr><td>Camera</td><td>Falcon 3EC</td></tr><tr><td>Voltage (kV)</td><td>300</td></tr><tr><td>Nominal magnification</td><td>75,000</td></tr><tr><td>Calibrated physical pixel size (Å)</td><td>1.06</td></tr><tr><td>Total exposure (e- /Å<sup>2</sup>)</td><td>42.7</td></tr><tr><td>Number of frames</td><td>30</td></tr><tr><th>Image processing</th><th/></tr><tr><td>Motion correction software</td><td>cryoSPARCv2</td></tr><tr><td>CTF estimation software</td><td>cryoSPARCv2</td></tr><tr><td>Particle selection software</td><td>cryoSPARCv2</td></tr><tr><td>3D map classification and refinement software</td><td>cryoSPARCv2</td></tr><tr><td>Micrographs used</td><td>2080</td></tr><tr><td>Particles selected</td><td>669,223</td></tr><tr><td>Global resolution (Å)</td><td>3.2</td></tr><tr><td>Particles contributing to final map</td><td>165,747</td></tr><tr><th>Model building</th><th/></tr><tr><td>Modeling software</td><td>Coot, phenix.real_space_refine</td></tr><tr><td>Number of residues built</td><td>3085</td></tr><tr><td>RMS (bonds)</td><td>0.002</td></tr><tr><td>RMS (angles)</td><td>0.56</td></tr><tr><td>Ramachandran favored (%)</td><td>95.8</td></tr><tr><td>Rotamer outliers (%)</td><td>0.5</td></tr><tr><td>Clashscore</td><td>6.27</td></tr><tr><td>MolProbity score</td><td>1.63</td></tr><tr><td>EMRinger score</td><td>2.54</td></tr></tbody></table></table-wrap><p>The angle between two Fab variable domains is ~126<sup>o</sup>, such that approximately three Fabs are required to complete one full turn of the spiral (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). The cryoEM structure of the 3D11 Fab-PbCSP complex and the crystal structures of the 3D11 Fab-peptide complexes are in remarkable agreement for both the Fab (backbone RMSD = 0.69 Å) and the PbCSP repeat region (backbone RMSD = 0.66 Å; <xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3</xref>). Minor differences exist in the N- and C-termini of the peptides, presumably because the termini are largely unrestricted in the crystal structures compared to the cryoEM structure.</p></sec><sec id="s2-5"><title>Contacts between 3D11 Fabs stabilize the PbCSP spiral structure</title><p>To access their repeating and densely-packed epitopes, 3D11 Fabs are closely arranged against one another in the 3D11 Fab-PbCSP complex. Indeed, the epitope for a single Fab can be defined by 14 residues (PPPPNPNDPPPPNP, <xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>), with the six C-terminal residues constituting the beginning of the epitope for the adjacent Fab. When considering two adjacent Fabs as a single binding unit, the BSA of the Fabs is 1313 Å<sup>2</sup>, and 1636 Å<sup>2</sup> for PbCSP. Interestingly, we observe multiple Fab-Fab contacts in the cryoEM structure (<xref ref-type="fig" rid="fig5">Figure 5</xref> and <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>). Comparison of the mAb 3D11 sequence to its inferred germline precursor (IGHV1-12 and IGKV1-135) reveals that some of the residues involved in these homotypic contacts have been somatically hypermutated (H.Tyr50 and H.Val56 in HCDR2, H.Asn58 and H.Thr73 in heavy chain (HC) framework region (FR) 3, and K.Tyr27D in KCDR1; <xref ref-type="fig" rid="fig5">Figure 5C</xref>). While H.Tyr50, H.Val56 and K.Tyr27D mediate Fab-Fab contacts in addition to directly interacting with PbCSP, H.Asn58 and H.Thr73 are only involved in Fab-Fab interactions.</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Homotypic interactions between 3D11 Fabs stabilize the 3D11 Fab-PbCSP complex.</title><p>(<bold>A</bold> and <bold>B</bold>) Close-up views of adjacent 3D11 Fabs from the cryoEM structure in complex with PbCSP (black). 3D11 Fabs bound to PbCSP form homotypic contacts with each adjacent Fab through two interfaces; one consisting of CDRs from the heavy and light chains of Fabs A and B (interface 1, <bold>A</bold>), and the second mediated by residues in FR3 of Fab A HC and FR3 of Fab C LC (interface 2, <bold>B</bold>). Variable domains of Fabs are shown in white. HCDR1, −2,–3, and KCDR1, −2 and −3 are colored yellow, orange, red, green, blue and purple, respectively. Residues forming Fab-Fab contacts are labeled with the position of the Fab in the cryoEM model (A, B or C) indicated in subscript. mAb 3D11 affinity-matured residues that engage in Fab-Fab contacts, but do not directly interact with PbCSP are highlighted in yellow with red font. Black dashed lines denote H-bonds. (<bold>C</bold>) Sequence alignment of mAb 3D11 with its inferred germline precursor. INT1 and INT2 refer to the two interfaces shown in (<bold>A</bold>) and (<bold>B</bold>). Green highlight: germline-encoded residues involved in homotypic interactions; Red: affinity-matured residues involved in homotypic interactions; Yellow highlight: affinity-matured residues involved in homotypic interactions that do not directly interact with PbCSP. (<bold>D</bold>) Binding affinity of WT 3D11 and H-58/73 germline-reverted mutant (Mut) Fabs to NPNDx1 (gray bars) and NPNDx2 (white bars) peptides as measured by ITC. Symbols represent independent measurements. Mean K<sub>D</sub> values resulting from at least two independent experiments are shown. Error bars represent standard error of the mean. An unpaired one-tailed t-test was performed using GraphPad Prism 8 to evaluate statistical significance: *p&lt;0.05.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-59018-fig5-v1.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Homotypic contacts between 3D11 Fabs in the 3D11 Fab-PbCSP cryoEM structure.</title><p>(<bold>A</bold>) Main interaction interfaces between adjacent 3D11 Fabs in the 3D11 Fab-PbCSP cryoEM structure. (<bold>B</bold>) Table of contacts between 3D11 Fabs. HB: hydrogen bond (3.8 Å cut-off).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-59018-fig5-figsupp1-v1.tif"/></fig><fig id="fig5s2" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 2.</label><caption><title>Negative-stain EM analysis of 3D11 IgG-PbCSP complexes.</title><p>(<bold>A</bold>) SEC chromatogram of 3D11 IgG-PbCSP complexes. (<bold>B</bold>) Representative negative-stain (NS) micrographs of particles present in selected SEC fractions: 1 – soluble aggregates, 2 - 3D11 IgG-PbCSP complexes, 3 – unbound 3D11 IgGs. Scale bars: 100 nm. (<bold>C</bold>) Comparison of NS 2D class averages of the 3D11 IgG-PbCSP complex (upper panels) to 2D class averages of the 3D11 Fab-PbCSP complex (lower panels).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-59018-fig5-figsupp2-v1.tif"/></fig><fig id="fig5s3" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 3.</label><caption><title>Comparison between cryoEM structures of 3D11 Fab-PbCSP and 311 Fab-PfCSP (PDB ID: 6MB3) (<xref ref-type="bibr" rid="bib61">Oyen et al., 2018</xref>).</title><p>CryoEM maps of the 3D11 Fab-PbCSP (<bold>A</bold> and <bold>E</bold>) and 311 Fab-PfCSP (<bold>C</bold> and <bold>G</bold>) complexes are shown as a transparent light gray surface with the CSP density highlighted in black for PbCSP and in blue for PfCSP. The CSP models built into the cryoEM maps are shown as gray for PbCSP; (<bold>B</bold> and <bold>F</bold>) or blue for PfCSP; (<bold>D</bold>) and <bold>H</bold>) sticks and aligned to the schematic representations of their respective protein sequences.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-59018-fig5-figsupp3-v1.tif"/></fig></fig-group><p>To investigate the role of affinity maturation in enhancing Fab-Fab contacts, somatically mutated HC residues H.Asn58 and H.Thr73 were reverted to their inferred germline precursors (N58S and T73K: subsequently named H-58/73; <xref ref-type="fig" rid="fig5">Figure 5C</xref>). We performed ITC studies to evaluate binding of wild-type (WT) and H-58/73 germline-reverted mutant 3D11 Fabs to two peptides derived from PbCSP, designed based on our X-ray and cryoEM structures to constitute the minimal binding site for one 3D11 Fab (PPPPNPNDPPPP, denoted ‘NPNDx1’) or two 3D11 Fabs in a ‘head-to-head’ conformation (PPPPNPNDPPPPNPNDPPPPNPND, denoted ‘NPNDx2’). Although both WT and H-58/73 germline-reverted mutant Fabs bound NPNDx1 with comparable affinity, WT 3D11 Fab demonstrated significantly greater affinity for NPNDx2 compared to NPNDx1 (KD values of 45 ± 6 nM and 127 ± 32 nM, respectively; <xref ref-type="fig" rid="fig5">Figure 5D</xref>). On the other hand, the H-58/73 germline-reverted mutant bound each peptide with similar affinities (KD values of 140 ± 38 nM for NPNDx2 and 160 ± 56 nM for NPNDx1; <xref ref-type="fig" rid="fig5">Figure 5D</xref>). The improved binding affinity of WT 3D11 Fab for NPNDx2 compared to NPNDx1, which is not observed for the H-58/73 germline-reverted mutant 3D11 Fab, suggests an important role for residues H.Asn58 and H.Thr73 in mediating homotypic interactions between neighboring 3D11 Fabs bound to PbCSP. Together, these data provide evidence for the affinity maturation of homotypic contacts that indirectly strengthen mAb 3D11 affinity to PbCSP.</p><p>To examine whether 3D11 IgG can induce a similar type of spiral conformation of PbCSP as 3D11 Fab, we prepared complexes of 3D11 IgG-PbCSP for negative-stain (ns) EM analysis. Incubation of PbCSP with excess 3D11 IgG resulted in significant precipitation of the sample, presumably due to IgG-induced crosslinking of PbCSP molecules (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2A–B</xref>). Nonetheless, a minor soluble fraction of the complex could be purified. Comparison of nsEM 2D class averages of this 3D11 IgG-PbCSP fraction to 2D class averages of the 3D11 Fab-PbCSP complex indicated that binding of either the 3D11 Fab or IgG can induce structural ordering of PbCSP into similar spiral conformations (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2C</xref>). Our findings are in agreement with a similar analysis previously performed with human 311 Fab and IgG in complex with PfCSP (<xref ref-type="bibr" rid="bib61">Oyen et al., 2018</xref>), which also observed the ability of both IgG and Fab to induce a spiral-like conformation in CSP.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>The CSP repeat is of broad interest for malaria vaccine design because it is targeted by inhibitory antibodies capable of preventing sporozoite infection as the parasite transits from <italic>Anopheles</italic> mosquitoes to mammalian hosts. Biophysical studies of the PfCSP central NANP repeat have shown that this region possesses low secondary structure propensities (<xref ref-type="bibr" rid="bib23">Dyson et al., 1990</xref>), and AFM studies on live Pf sporozoites suggest a range of conformations for PfCSP (<xref ref-type="bibr" rid="bib63">Patra et al., 2017</xref>; <xref ref-type="bibr" rid="bib31">Herrera et al., 2015</xref>). Importantly, recent studies have uncovered that some of the most potent antibodies against the PfCSP repeat region are cross-reactive with the PfCSP N-terminal junction, which harbors KQPA, NPDP and NVDP motifs interspersed with NANP motifs (<xref ref-type="bibr" rid="bib42">Kisalu et al., 2018</xref>; <xref ref-type="bibr" rid="bib56">Murugan et al., 2020</xref>; <xref ref-type="bibr" rid="bib91">Tan et al., 2018</xref>). Our MD simulations of different sub-regions of the PfCSP central repeat, including the N-junction, provided detailed descriptions of their conformational ensemble and revealed that each sequence motif possesses a similarly low structural propensity.</p><p>Our MD simulations for PbCSP also indicated that the low structural propensity of central repeat motifs with subtle sequence variance extends to other <italic>Plasmodium</italic> species. These findings are in agreement with studies linking repetitive, low-complexity peptide sequences to structural disorder (<xref ref-type="bibr" rid="bib72">Rauscher and Pomès, 2012</xref>; <xref ref-type="bibr" rid="bib73">Rauscher and Pomès, 2017</xref>; <xref ref-type="bibr" rid="bib75">Romero et al., 2001</xref>). The role of the numerous repetitive sequences observed in parasitic genomes (<xref ref-type="bibr" rid="bib90">Tan et al., 2010</xref>; <xref ref-type="bibr" rid="bib52">Mendes et al., 2013</xref>; <xref ref-type="bibr" rid="bib17">Davies et al., 2017</xref>) remains to be fully understood, but is postulated to include maximizing parasite interactions with the target host cell (<xref ref-type="bibr" rid="bib52">Mendes et al., 2013</xref>), allowing the parasite to adapt under selective pressure by varying its number of repeats (<xref ref-type="bibr" rid="bib17">Davies et al., 2017</xref>), and impairing the host immune response (<xref ref-type="bibr" rid="bib46">Ly and Hansen, 2019</xref>; <xref ref-type="bibr" rid="bib68">Portugal et al., 2015</xref>; <xref ref-type="bibr" rid="bib88">Sullivan et al., 2015</xref>).</p><p>Binding of the PfCSP repeat by inhibitory antibodies has been shown to induce various conformations in this intrinsically disordered region (<xref ref-type="bibr" rid="bib38">Imkeller et al., 2018</xref>; <xref ref-type="bibr" rid="bib42">Kisalu et al., 2018</xref>; <xref ref-type="bibr" rid="bib56">Murugan et al., 2020</xref>; <xref ref-type="bibr" rid="bib60">Oyen et al., 2017</xref>; <xref ref-type="bibr" rid="bib91">Tan et al., 2018</xref>; <xref ref-type="bibr" rid="bib93">Triller et al., 2017</xref>; <xref ref-type="bibr" rid="bib84">Scally and Julien, 2018</xref>; <xref ref-type="bibr" rid="bib65">Pholcharee et al., 2020</xref>). Here, we show that the PbCSP repeat adopts an extended and bent conformation when recognized by inhibitory mAb 3D11. Antibody recognition of the PfCSP repeat is often mediated by aromatic cages formed by the paratope, which surround prolines, backbone atoms, and aliphatic portions of side chains in the epitope (<xref ref-type="bibr" rid="bib56">Murugan et al., 2020</xref>; <xref ref-type="bibr" rid="bib65">Pholcharee et al., 2020</xref>). Antibody paratope residues partaking in aromatic cages often include germline-encoded residues, such as H.Trp52 from VH3-33 signature genes that are strongly recruited in the humoral response against PfCSP (<xref ref-type="bibr" rid="bib40">Julien and Wardemann, 2019</xref>; <xref ref-type="bibr" rid="bib65">Pholcharee et al., 2020</xref>; <xref ref-type="bibr" rid="bib55">Murugan et al., 2018</xref>). Similarly, murine mAb 3D11 uses eight aromatic residues to recognize the PbCSP repeat. Germline-encoded K.Tyr32 appears to play a central role in mAb 3D11 PbCSP recognition by contacting consecutive Asn-Asp-Pro residues (PN(A/P)<underline>NDP</underline>(A/P)P) in the middle of the core epitope, contributing 58 Å<sup>2</sup> of BSA on the Fab. These findings indicate a central role for germline-encoded aromatic residues in antibody binding of Plasmodium CSP repeats across species.</p><p>Our structural and biophysical data demonstrated that mAb 3D11 is cross-reactive and binds the different repeat motifs of PbCSP in nearly identical conformations. Such cross-reactivity for the repeat motifs of subtle differences in PfCSP is also exhibited by inhibitory human antibodies encoded by a variety of Ig-gene combinations (<xref ref-type="bibr" rid="bib42">Kisalu et al., 2018</xref>; <xref ref-type="bibr" rid="bib56">Murugan et al., 2020</xref>; <xref ref-type="bibr" rid="bib91">Tan et al., 2018</xref>; <xref ref-type="bibr" rid="bib93">Triller et al., 2017</xref>; <xref ref-type="bibr" rid="bib83">Scally et al., 2018</xref>). Notably, the inferred germline precursor genes of mAb 3D11 (IGHV1-12/IGKV1-135) share the most sequence similarity with the human IGHV1-3/IGKV2-30 genes (68% and 82% sequence identity, respectively); IGHV1-3 is the inferred germline precursor of the potent, cross-reactive human mAb CIS43 (<xref ref-type="bibr" rid="bib42">Kisalu et al., 2018</xref>). Moreover, it was previously reported that human anti-PfCSP antibody affinity is often directly associated with epitope cross-reactivity (<xref ref-type="bibr" rid="bib56">Murugan et al., 2020</xref>). While mAb 3D11 provides one such example in mice, further investigation is needed to determine whether favorable selection of cross-reactive clones during B cell maturation has evolved as a common mechanism of the immune response in mammals against Plasmodium CSP.</p><p>Most residues that mediate mAb 3D11 contacts with the PbCSP repeat are germline-encoded; indeed, of nine affinity-matured residues in the HC and three in the KC, only three are involved in direct contacts with the antigen (H.Trp50, H.Val56 and K.Tyr27D). Due to the repetitive nature of the central repeat motifs, multiple antibodies bind simultaneously to one CSP protein and neighboring Fabs engage in homotypic interactions (<xref ref-type="bibr" rid="bib38">Imkeller et al., 2018</xref>; <xref ref-type="bibr" rid="bib61">Oyen et al., 2018</xref>). Our data suggest that somatic mutations of residues that partake in Fab-Fab contacts enhance homotypic interactions and indirectly improve the binding affinity of the mAb to CSP. In this respect, mAb 3D11 recognition of PbCSP resembles binding of some neutralizing human mAbs to PfCSP (<xref ref-type="bibr" rid="bib38">Imkeller et al., 2018</xref>; <xref ref-type="bibr" rid="bib56">Murugan et al., 2020</xref>; <xref ref-type="bibr" rid="bib61">Oyen et al., 2018</xref>). In human mAbs 311 (<xref ref-type="bibr" rid="bib61">Oyen et al., 2018</xref>) and 1210 (<xref ref-type="bibr" rid="bib38">Imkeller et al., 2018</xref>), CDR3 regions of both heavy and light chains appear to play a considerable role in forming Fab-Fab contacts. Interestingly, in the case of mAb 3D11, homotypic interactions are mainly mediated by residues localized in HCDR1 and −2, KCDR1, and FR3 regions of both the HC and KC, with little contribution from residues in the CDR3 regions (with the exception of H.Tyr97 in HCDR3 and K.Phe94 in KCDR3). Taken together, these findings indicate that homotypic interactions are a feature by which the mammalian immune system can robustly engage repetitive Plasmodium antigens with high affinity in various ways. Interestingly, recent studies have reported that Fab-Fab interactions occur in other antibody-antigen complexes, providing evidence that homotypic contacts can drive diverse biology: for example, homotypic interactions were found between two nanobodies bound to a pentameric antigen (<xref ref-type="bibr" rid="bib5">Bernedo-Navarro et al., 2018</xref>), and between two Rituximab antibodies bound to B cell membrane protein CD20 (<xref ref-type="bibr" rid="bib78">Rougé et al., 2020</xref>).</p><p>Our cryoEM analysis also revealed how the PbCSP repeat, like that of PfCSP, can adopt a highly organized spiral structure upon mAb binding. Such spiral assembly of CSP was previously observed upon human mAb 311 Fab and IgG binding, which induced a PfCSP spiral with a greater diameter (27 Å) and smaller pitch (49 Å) compared to the 3D11-PbCSP complex (16 Å diameter and 51 Å pitch) (<xref ref-type="bibr" rid="bib61">Oyen et al., 2018</xref>; <xref ref-type="fig" rid="fig5s3">Figure 5—figure supplement 3</xref>). Differences in the architecture between these two complexes can be attributed to the fact that mAbs 3D11 and 311 recognize their respective antigens in distinct conformations. Because different anti-CSP inhibitory antibodies can bind the repeat region in a variety of conformations (<xref ref-type="bibr" rid="bib38">Imkeller et al., 2018</xref>; <xref ref-type="bibr" rid="bib42">Kisalu et al., 2018</xref>; <xref ref-type="bibr" rid="bib91">Tan et al., 2018</xref>; <xref ref-type="bibr" rid="bib93">Triller et al., 2017</xref>; <xref ref-type="bibr" rid="bib84">Scally and Julien, 2018</xref>), it is likely that many types of CSP-antibody assemblies exist. Further studies are needed to investigate whether the formation of such highly organized complexes is possible on the surface of live sporozoites and how antibody-CSP interactions occur in the context of polyclonal serum. These insights will be important for our structure-function understanding of the mechanisms employed by these repeat-targeting antibodies to inhibit sporozoite development, migration and infection of hepatocytes.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th>Reagent type <break/>(species) or resource</th><th>Designation</th><th>Source or reference</th><th>Identifiers</th><th>Additional information</th></tr></thead><tbody><tr><td> Recombinant DNA reagent</td><td>pcDNA3.4-3D11 Fab HC (plasmid)</td><td>This paper</td><td>N/A</td><td>3D11 Fab heavy chain gene in pcDNA3.4 TOPO vector</td></tr><tr><td> Recombinant DNA reagent</td><td>pcDNA3.4-3D11 Fab 58/73 HC (plasmid)</td><td>This paper</td><td>N/A</td><td>3D11 Fab germline-reverted mutant heavy chain gene in pcDNA3.4 TOPO vector</td></tr><tr><td> Recombinant DNA reagent</td><td>pcDNA3.4-3D11 Fab KC (plasmid)</td><td>This paper</td><td>N/A</td><td>3D11 Fab light chain gene in pcDNA3.4 TOPO vector</td></tr><tr><td> Recombinant DNA reagent</td><td>pcDNA3.4-PbCSP-6xHis (plasmid)</td><td>This paper</td><td>N/A</td><td>PbCSP gene with His tag in pcDNA3.4 TOPO vector</td></tr><tr><td> Recombinant DNA reagent</td><td>pcDNA3.4-PbC-CSP-6xHis (plasmid)</td><td>This paper</td><td>N/A</td><td>PbC-CSP gene with His tag in pcDNA3.4 TOPO vector</td></tr><tr><td> Recombinant DNA reagent</td><td>pcDNA3.4-PbCSP-αTSR-6xHis (plasmid)</td><td>This paper</td><td>N/A</td><td>PbCSP αTSR gene with His tag in pcDNA3.4 TOPO vector</td></tr><tr><td> Cell line (<italic>Homo sapiens</italic>)</td><td>FreeStyle 293 F cells</td><td>Thermo Fisher Scientific</td><td>Cat# R79007</td><td/></tr><tr><td> Cell line (<italic>Mus musculus</italic>)</td><td>3D11 hybridoma cell line</td><td><xref ref-type="bibr" rid="bib95">Yoshida et al., 1980</xref></td><td>BEI Resources #MRA-100; RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2650479">AB_2650479</ext-link></td><td/></tr><tr><td> Chemical compound</td><td>GIBCO FreeStyle 293 Expression Medium</td><td>Thermo Fisher Scientific</td><td>Cat# 12338026</td><td/></tr><tr><td> Chemical compound</td><td>GIBCO Hybridoma-SFM</td><td>Thermo Fisher Scientific</td><td>Cat# 12045076</td><td/></tr><tr><td> Chemical compound</td><td>FectoPRO DNA Transfection Reagent</td><td>VWR</td><td>Cat# 10118–444</td><td/></tr><tr><td> Chemical compound</td><td>Fetal bovine serum</td><td>Thermo Fisher Scientific</td><td>Cat# 12483–020</td><td/></tr><tr><td> Antibody</td><td>3D11 IgG (mouse monoclonal)</td><td><xref ref-type="bibr" rid="bib95">Yoshida et al., 1980</xref></td><td>N/A</td><td>Purified from 3D11 hybridoma cell line; See Materials and methods</td></tr><tr><td> Recombinant protein</td><td>3D11 Fab</td><td>This paper</td><td>N/A</td><td>See Materials and methods for concentrations and masses used, and buffer conditions</td></tr><tr><td> Recombinant protein</td><td>3D11 Fab H-58/73</td><td>This paper</td><td>N/A</td><td>See Materials and methods for concentrations and masses used, and buffer conditions</td></tr><tr><td> Recombinant protein</td><td>PbCSP</td><td>This paper</td><td>N/A</td><td>See Materials and methods for concentrations and masses used, and buffer conditions</td></tr><tr><td> Peptide</td><td>PAPP (PAPPNANDPAPPNAND)</td><td>This paper</td><td>N/A</td><td>Derived from PbCSP repeat region</td></tr><tr><td> Peptide</td><td>NAND (PPPPNANDPPPPNAND)</td><td>This paper</td><td>N/A</td><td>Derived from PbCSP repeat region</td></tr><tr><td> Peptide</td><td>NPND (PPPPNPNDPPPPNPND)</td><td>This paper</td><td>N/A</td><td>Derived from PbCSP repeat region</td></tr><tr><td> Peptide</td><td>Mixed (PPPPNPNDPAPPNAND)</td><td>This paper</td><td>N/A</td><td>Derived from PbCSP repeat region</td></tr><tr><td> Peptide</td><td>NPNDx1 (PPPPNPNDPPPP)</td><td>This paper</td><td>N/A</td><td>Derived from PbCSP repeat region</td></tr><tr><td> Peptide</td><td>NPNDx2 (PPPPNPNDPPPPNPNDPPPPNPND)</td><td>This paper</td><td>N/A</td><td>Derived from PbCSP repeat region</td></tr><tr><td> Software, algorithm</td><td>GROMACS 5.1.4</td><td><xref ref-type="bibr" rid="bib1">Abraham et al., 2015</xref>; <xref ref-type="bibr" rid="bib4">Berendsen et al., 1995</xref></td><td><ext-link ext-link-type="uri" xlink:href="http://manual.gromacs.org/documentation/5.1.4/">http://manual.gromacs.org/documentation/5.1.4/</ext-link>; RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_014565">SCR_014565</ext-link></td><td/></tr><tr><td> Software, algorithm</td><td>LINCS</td><td><xref ref-type="bibr" rid="bib32">Hess et al., 1997</xref>; <xref ref-type="bibr" rid="bib33">Hess, 2008</xref></td><td>N/A</td><td/></tr><tr><td> Software, algorithm</td><td>Particle-Mesh Ewald algorithm</td><td><xref ref-type="bibr" rid="bib15">Darden et al., 1993</xref>; <xref ref-type="bibr" rid="bib26">Essmann et al., 1995</xref></td><td>N/A</td><td/></tr><tr><td> Software, algorithm</td><td>Nosé-Hoover thermostat</td><td><xref ref-type="bibr" rid="bib57">Nosé, 1984</xref>; <xref ref-type="bibr" rid="bib34">Hoover, 1985</xref></td><td>N/A</td><td/></tr><tr><td> Software, algorithm</td><td>Parrinello-Rahman algorithm</td><td><xref ref-type="bibr" rid="bib62">Parrinello and Rahman, 1981</xref></td><td>N/A</td><td/></tr><tr><td> Software, algorithm</td><td>VMD</td><td><xref ref-type="bibr" rid="bib35">Humphrey et al., 1996</xref></td><td><ext-link ext-link-type="uri" xlink:href="https://www.ks.uiuc.edu/Research/vmd/">https://www.ks.uiuc.edu/Research/vmd/</ext-link>; RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_001820">SCR_001820</ext-link></td><td/></tr><tr><td> Software, algorithm</td><td>Matplotlib</td><td><xref ref-type="bibr" rid="bib36">Hunter, 2007</xref></td><td><ext-link ext-link-type="uri" xlink:href="https://matplotlib.org/">https://matplotlib.org/</ext-link>; RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_008624">SCR_008624</ext-link></td><td/></tr><tr><td> Software, algorithm</td><td>Octet Data Analysis Software 9.0.0.6</td><td>ForteBio</td><td><ext-link ext-link-type="uri" xlink:href="https://www.fortebio.com/products/octet-systems-software">https://www.fortebio.com/products/octet-systems-software</ext-link></td><td/></tr><tr><td> Software, algorithm</td><td>MicroCal ITC Origin 7.0 Analysis Software</td><td>Malvern</td><td><ext-link ext-link-type="uri" xlink:href="https://www.malvernpanalytical.com/">https://www.malvernpanalytical.com/</ext-link></td><td/></tr><tr><td> Software, algorithm</td><td>ASTRA</td><td>Wyatt</td><td><ext-link ext-link-type="uri" xlink:href="https://www.wyatt.com/products/software/astra.html">https://www.wyatt.com/products/software/astra.html</ext-link>; RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_016255">SCR_016255</ext-link></td><td/></tr><tr><td> Software, algorithm</td><td>GraphPad Prism 8</td><td>GraphPad Software</td><td><ext-link ext-link-type="uri" xlink:href="https://www.graphpad.com/">https://www.graphpad.com/</ext-link>; RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_002798">SCR_002798</ext-link></td><td/></tr><tr><td> Software, algorithm</td><td>EPU</td><td>ThermoFisher Scientific</td><td><ext-link ext-link-type="uri" xlink:href="https://www.fei.com/software/">https://www.fei.com/software/</ext-link></td><td/></tr><tr><td> Software, algorithm</td><td>SBGrid</td><td>SBGrid Consortium</td><td><ext-link ext-link-type="uri" xlink:href="https://sbgrid.org/">https://sbgrid.org/</ext-link>; RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_003511">SCR_003511</ext-link></td><td/></tr><tr><td> Software, algorithm</td><td>cryoSPARC v2</td><td><xref ref-type="bibr" rid="bib70">Punjani et al., 2017</xref></td><td><ext-link ext-link-type="uri" xlink:href="https://cryosparc.com/">https://cryosparc.com/</ext-link></td><td/></tr><tr><td> Software, algorithm</td><td>Phenix (phenix.refine; phenix.real_space_refine)</td><td><xref ref-type="bibr" rid="bib2">Adams et al., 2010</xref></td><td><ext-link ext-link-type="uri" xlink:href="https://www.phenix-online.org/">https://www.phenix-online.org/</ext-link>; RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_014224">SCR_014224</ext-link></td></tr><tr><td> Software, algorithm</td><td>UCSF Chimera</td><td><xref ref-type="bibr" rid="bib64">Pettersen et al., 2004</xref></td><td><ext-link ext-link-type="uri" xlink:href="https://www.cgl.ucsf.edu/chimera/">https://www.cgl.ucsf.edu/chimera/</ext-link>; RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_004097">SCR_004097</ext-link></td><td/></tr><tr><td> Software, algorithm</td><td>UCSF ChimeraX</td><td><xref ref-type="bibr" rid="bib29">Goddard et al., 2018</xref></td><td><ext-link ext-link-type="uri" xlink:href="https://www.cgl.ucsf.edu/chimerax/">https://www.cgl.ucsf.edu/chimerax/</ext-link>; RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_015872">SCR_015872</ext-link></td><td/></tr><tr><td> Software, algorithm</td><td>Coot</td><td><xref ref-type="bibr" rid="bib25">Emsley et al., 2010</xref></td><td><ext-link ext-link-type="uri" xlink:href="https://www2.mrc-lmb.cam.ac.uk/personal/pemsley/coot/">https://www2.mrc-lmb.cam.ac.uk/personal/pemsley/coot/</ext-link>; RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_014222">SCR_014222</ext-link></td><td/></tr><tr><td> Software, algorithm</td><td>PyMOL</td><td>The PyMOL Molecular Graphics System, Version 1.8 Schrödinger, LLC.</td><td><ext-link ext-link-type="uri" xlink:href="https://pymol.org/2/#products">https://pymol.org/2/#products</ext-link>; RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_000305">SCR_000305</ext-link></td><td/></tr><tr><td> Software, algorithm</td><td>PDBePISA</td><td><xref ref-type="bibr" rid="bib43">Krissinel and Henrick, 2007</xref></td><td><ext-link ext-link-type="uri" xlink:href="https://www.ebi.ac.uk/pdbe/pisa/">https://www.ebi.ac.uk/pdbe/pisa/</ext-link>; RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_015749">SCR_015749</ext-link></td><td/></tr><tr><td> Other</td><td>Homemade holey gold grids</td><td><xref ref-type="bibr" rid="bib48">Marr et al., 2014</xref></td><td>N/A</td><td/></tr><tr><td> Other</td><td>Homemade carbon grids</td><td><xref ref-type="bibr" rid="bib8">Booth et al., 2011</xref></td><td>N/A</td><td/></tr></tbody></table></table-wrap><sec id="s4-1"><title>Molecular dynamics simulations</title><p>We performed all-atom molecular dynamics simulations of the following peptides: (NPNA)<sub>5</sub>, KQPADGNPDPNANPN, NPDPNANPNVDPNANP, (NVDPNANP)<sub>2</sub>NVDP, (PPPPNPND)<sub>2</sub>, (PPPPNAND)<sub>2</sub>, (PAPPNAND)<sub>2</sub>, and PPPPNPNDPAPPNAND as blocked monomers in water with 0.15 M NaCl. Each simulation system consisted of the respective peptide with an acetylated N-terminus and amidated C-terminus solvated in a dodecahedral box with side lengths of 4.9 nm.</p><p>The systems were simulated using the program GROMACS 5.1.4 (67, 68) with the CHARMM22* (<xref ref-type="bibr" rid="bib66">Piana et al., 2011</xref>; <xref ref-type="bibr" rid="bib6">Best and Hummer, 2009</xref>; <xref ref-type="bibr" rid="bib44">Lindorff-Larsen et al., 2012</xref>; <xref ref-type="bibr" rid="bib7">Best and Mittal, 2010</xref>; <xref ref-type="bibr" rid="bib47">MacKerell et al., 1998</xref>) force field for the protein and the TIP3P (<xref ref-type="bibr" rid="bib39">Jorgensen et al., 1983</xref>) water model. All simulations were performed with periodic boundary conditions at a constant pressure and temperature of 1 bar and 300 K, respectively. The LINCS algorithm was used to constrain all bond lengths (<xref ref-type="bibr" rid="bib32">Hess et al., 1997</xref>; <xref ref-type="bibr" rid="bib33">Hess, 2008</xref>). A cut-oﬀ of 1.4 nm was used for Lennard-Jones interactions. The Particle-Mesh Ewald algorithm (<xref ref-type="bibr" rid="bib15">Darden et al., 1993</xref>; <xref ref-type="bibr" rid="bib26">Essmann et al., 1995</xref>) was used to calculate long-range electrostatics interactions with a Fourier spacing of 0.12 and an interpolation order of 4. The Nosé-Hoover thermostat (<xref ref-type="bibr" rid="bib57">Nosé, 1984</xref>; <xref ref-type="bibr" rid="bib34">Hoover, 1985</xref>) was used for temperature coupling with the peptide and solvent coupled to two temperature baths and a time constant of 0.1 ps. The Parrinello-Rahman algorithm (<xref ref-type="bibr" rid="bib62">Parrinello and Rahman, 1981</xref>) was used for pressure coupling with a time constant of 2 ps. The integration step size was two fs and the system coordinates were stored every 10 ps.</p><p>The simulations were performed for 300 ns for 20 independent replicas of (NPNA)<sub>5</sub> and 10 independent replicas of all other sequences. The initial structures of the peptides were selected from 10 ns simulations in which extended conformations of the peptides were collapsed <italic>in vacuo</italic>. The ﬁrst 100 ns of each trajectory were omitted as the time required for system relaxation based on the convergence analysis of the radius of gyration (Rg) shown in <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>. This protocol resulted in a total of 4 μs of production time for the (NPNA)<sub>5</sub> dataset and a total of 2 μs of production time for the other systems, which was used to compute equilibrium ensemble properties. The peptide snapshots were generated with VMD (<xref ref-type="bibr" rid="bib35">Humphrey et al., 1996</xref>) and the plots were created with Matplotlib (<xref ref-type="bibr" rid="bib36">Hunter, 2007</xref>).</p></sec><sec id="s4-2"><title>3D11 Fab production and purification</title><p>The mAb 3D11 hybridoma cell line variable light and heavy chain antibody genes were sequenced (Applied Biological Materials Inc). mAb 3D11 V<sub>K</sub> and V<sub>H</sub> regions were cloned individually into custom pcDNA3.4 expression vectors immediately upstream of human Igκ and Igγ1-C<sub>H</sub>1 domains, respectively. The resulting pcDNA3.4-3D11 Fab KC and −3D11 Fab HC or −3D11 Fab 58/73 HC plasmids were co-transfected into FreeStyle 293 F cells for transient expression using FectoPRO DNA Transfection Reagent, cultured in GIBCO FreeStyle 293 Expression Medium, and purified via KappaSelect affinity chromatography (GE Healthcare), cation exchange chromatography (MonoS, GE Healthcare), and size-exclusion chromatography (Superdex 200 Increase 10/300 GL, GE Healthcare).</p></sec><sec id="s4-3"><title>3D11 IgG production and purification</title><p>The mAb 3D11 hybridoma cell line (BEI Resources MRA-100) was cultured in GIBCO Hybridoma-SFM (Thermo Fisher Scientific Cat#12045076) with 2.5–10% fetal bovine serum (Thermo Fisher Scientific Cat#12483–020). Cells were harvested and the supernatant containing 3D11 IgG was purified via Protein G affinity chromatography (GE Healthcare) and size-exclusion chromatography (Superose 6 Increase 10/300 GL, GE Healthcare).</p></sec><sec id="s4-4"><title>Recombinant PbCSP production and purification</title><p>Constructs of full-length PbCSP (residues 24–318), the PbCSP C-terminal domain (residues 202–318; PbC-CSP) and the PbCSP αTSR domain (residues 263–318; PbCSP αTSR) from strain ANKA (NCBI reference sequence XP_022712148.1) were designed with potential N-linked glycosylation sites mutated to glutamine and cloned into pcDNA3.4 expression vectors with a His tag. The resulting pcDNA3.4-PbCSP-6xHis, -PbC-CSP-6xHis and -PbCSP-αTSR-6xHis plasmids were transiently transfected in FreeStyle 293 F cells using FectoPRO DNA Transfection Reagent, cultured in GIBCO FreeStyle 293 Expression Medium, and purified by HisTrap FF affinity chromatography (GE Healthcare) and size-exclusion chromatography (Superdex 200 Increase 10/300 GL, GE Healthcare).</p></sec><sec id="s4-5"><title>Cell lines</title><p>FreeStyle 293 F cells (Thermo Fisher Scientific 12338026) and 3D11 hybridoma cell line (BEI Resources MRA-100) were authenticated and validated to be mycoplasma-free by their respective commercial entities.</p></sec><sec id="s4-6"><title>Binding kinetics by biolayer interferometry</title><p>BLI (Octet RED96, FortéBio) experiments were conducted to determine the binding kinetics of the 3D11 Fab to recombinant PbCSP. PbCSP, PbC-CSP or PbCSP αTSR was diluted to 10 µg/ml in kinetics buffer (PBS, pH 7.4, 0.01% [w/v] BSA, 0.002% [v/v] Tween-20) and immobilized onto Ni-NTA (NTA) biosensors (FortéBio). After a steady baseline was established, biosensors were dipped into wells containing twofold dilutions of 3D11 Fab in kinetics buffer. Tips were then immersed back into kinetics buffer for measurement of the dissociation rate. Kinetics data were analyzed using the FortéBio’s Octet Data Analysis software 9.0.0.6, and curves were fitted to a 2:1 binding model.</p></sec><sec id="s4-7"><title>Binding thermodynamics by isothermal titration calorimetry</title><p>Calorimetric titration experiments were performed with an Auto-iTC<sub>200</sub> instrument (Malvern) at 37°C. Full-length PbCSP and PbCSP-derived peptides (PAPP, NAND, NPND, Mixed, NPNDx1, NPNDx2; GenScript) were diluted in Tris-buffered saline (TBS; 20 mM Tris pH 8.0, and 150 mM NaCl) and added to the calorimetric cell. Titrations were performed with 3D11 Fab in the syringe, diluted in TBS, in 15 successive injections of 2.5 μl. Full-length PbCSP was diluted to 5 μM and titrated with 3D11 Fab at 400 μM. All PbCSP-derived peptides were diluted to 20 μM and titrated with 3D11 Fab at 200–300 μM; with the exception of the NPNDx2 peptide, which was diluted to 9–10 μM and titrated with 180–200 μM 3D11 Fab. Experiments were performed at least two times, and the mean and standard error of the mean are reported. The experimental data were analyzed using the MicroCal ITC Origin 7.0 Analysis Software according to a 1:1 binding model.</p></sec><sec id="s4-8"><title>Size-exclusion chromatography-multi-angle light scattering (SEC-MALS)</title><p>Full-length PbCSP was complexed with a molar excess of 3D11 Fab and loaded on a Superose 6 Increase 10/300 GL (GE Healthcare) using an Agilent Technologies 1260 Infinity II HPLC coupled in-line with the following calibrated detectors: (i) MiniDawn Treos MALS detector (Wyatt); (ii) Quasielastic light scattering (QELS) detector (Wyatt); and (iii) Optilab T-reX refractive index (RI) detector (Wyatt). Data processing was performed using the ASTRA software (Wyatt).</p></sec><sec id="s4-9"><title>Crystallization and structure determination</title><p>Purified 3D11 Fab was concentrated and diluted to 5 mg/mL with each of the PAPP, NAND and Mixed peptides in a 1:5 molar ratio; and diluted to 2.1 mg/mL with the NPND peptide in a 1:5 molar ratio. The 3D11 Fab/PAPP complex was mixed in a 1:1 ratio with 20% (w/v) PEG 3350, 0.15 M malic acid pH 7. Crystals appeared after ~1 d and were cryoprotected in 15% (v/v) ethylene glycol before being flash-frozen in liquid nitrogen. The 3D11 Fab/NAND complex was mixed in a 1:1 ratio with 20% (w/v) PEG 3350, 0.2 M di-sodium tartrate. Crystals appeared after ~3 d and were cryoprotected in 15% (v/v) ethylene glycol before being flash-frozen in liquid nitrogen. The 3D11 Fab/NPND complex was mixed in a 1:1 ratio with 25% (w/v) PEG 3350, 0.2 M lithium sulfate, 0.1 M Tris pH 8.5. Crystals appeared after ~12 d and were cryoprotected in 20% (v/v) ethylene glycol before being flash-frozen in liquid nitrogen. The 3D11 Fab/Mixed complex was mixed in a 1:1 ratio with 25.5% (w/v) PEG 4000, 15% (v/v) glycerol, 0.17 M ammonium acetate, 0.085 M sodium citrate pH 5.6. Crystals appeared after ~1 d and were cryoprotected in 20% (v/v) glycerol before being flash-frozen in liquid nitrogen.</p><p>Data were collected at the 23-ID-D or 23-ID-B beamline at the Argonne National Laboratory Advanced Photon Source, or at the 17-ID-1 beamline at the National Synchrotron Light Source II. All datasets were processed and scaled using XDS (<xref ref-type="bibr" rid="bib41">Kabsch, 2010</xref>). The structures were determined by molecular replacement using Phaser (<xref ref-type="bibr" rid="bib50">McCoy et al., 2007</xref>). Refinement of the structures was performed using phenix.refine (<xref ref-type="bibr" rid="bib2">Adams et al., 2010</xref>) and iterations of refinement using Coot (<xref ref-type="bibr" rid="bib25">Emsley et al., 2010</xref>). Access to all software was supported through SBGrid (<xref ref-type="bibr" rid="bib54">Morin et al., 2013</xref>).</p></sec><sec id="s4-10"><title>CryoEM data collection and image processing</title><p>The PbCSP/3D11 complex was concentrated to 3 mg/mL and incubated briefly with 0.01% (w/v) n-Dodecyl β-D-maltopyranoside. 3 µl of the sample was deposited on homemade holey gold grids (<xref ref-type="bibr" rid="bib48">Marr et al., 2014</xref>), which were glow-discharged in air for 15 s before use. Sample was blotted for 12.5 s, and subsequently plunge-frozen in a mixture of liquid ethane and propane (<xref ref-type="bibr" rid="bib92">Tivol et al., 2008</xref>) using a modified FEI Vitrobot (maintained at 4°C and 100% humidity). Data collection was performed on a Thermo Fisher Scientific Titan Krios G3 operated at 300 kV with a Falcon 3EC camera automated with the EPU software. A nominal magnification of 75,000× (calibrated pixel size of 1.06 Å) and defocus range between 1.6 and 2.2 μm were used for data collection. Exposures were fractionated as movies of 30 frames with a total exposure of 42.7 electrons/Å<sup>2</sup>. A total of 2080 raw movies were obtained.</p><p>Image processing was carried out in cryoSPARC v2 (<xref ref-type="bibr" rid="bib70">Punjani et al., 2017</xref>). Initial specimen movement correction, exposure weighting, and CTF parameters estimation were done using patch-based algorithms. Manual particle selection was performed on 30 micrographs to create templates for template-based picking. 669,223 particle images were selected by template picking and individual particle images were corrected for beam-induced motion with the local motion algorithm (<xref ref-type="bibr" rid="bib82">Rubinstein and Brubaker, 2015</xref>). <italic>Ab-initio</italic> structure determination revealed that most particles present in the dataset correspond to the 3D11 Fab-PbCSP complex, with a minor population of particles corresponding to unbound 3D11 Fab. After several rounds of heterogeneous refinement, 165,747 particle images were selected for non-uniform refinement with no symmetry applied, which resulted in a 3.2 Å resolution map of the 3D11 Fab-PbCSP complex estimated from the gold-standard Fourier shell correlation (FSC) criterion.</p></sec><sec id="s4-11"><title>CryoEM model building</title><p>To create a starting model of the 3D11 Fab-PbCSP complex, seven copies of 3D11 Fab/PbCSP-peptide crystal structures were manually docked into the 3D11 Fab-PbCSP cryoEM map using UCSF Chimera (<xref ref-type="bibr" rid="bib64">Pettersen et al., 2004</xref>), followed by manual building using Coot (<xref ref-type="bibr" rid="bib25">Emsley et al., 2010</xref>). All models were refined using phenix.real_space_refine (<xref ref-type="bibr" rid="bib2">Adams et al., 2010</xref>) with secondary structure and geometry restraints. The final models were evaluated by MolProbity (<xref ref-type="bibr" rid="bib10">Chen et al., 2010</xref>). The figures were prepared with UCSF Chimera (<xref ref-type="bibr" rid="bib64">Pettersen et al., 2004</xref>) and UCSF ChimeraX (<xref ref-type="bibr" rid="bib29">Goddard et al., 2018</xref>). Contacts in the 3D11 Fab-PbCSP complex were identified by PDBePISA (<xref ref-type="bibr" rid="bib43">Krissinel and Henrick, 2007</xref>).</p></sec><sec id="s4-12"><title>Negative-stain EM of 3D11 IgG-PbCSP complex</title><p>To obtain soluble complexes of 3D11-IgG-PbCSP for NS analysis, 8.4 µg of PbCSP was incubated overnight with 20x molar excess of 3D11 IgG. After removal of aggregates via centrifugation, 3D11 IgG-PbCSP complexes were purified on a Superose 6 Increase 10/300 GL column (GE Healthcare). Fractions containing complexes of 3D11 IgG-PbCSP were pooled and concentrated, and subsequently deposited at approximately 50 µg/mL onto homemade carbon grids and stained with 2% uranyl formate. Data were collected with a FEI Tecnai T20 electron microscope operating at 200 kV, and acquired with an Orius charge-coupled device (CCD) camera (Gatan Inc) at a calibrated 34,483X magnification, resulting in a pixel size of 2.71 Å. Particle picking, extraction and three rounds of 2D classification with 50 classes allowed were performed with cryoSPARC v2 (<xref ref-type="bibr" rid="bib70">Punjani et al., 2017</xref>).</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>We are grateful to Dr. Samir Benlekbir for help with cryoEM data collection and for advice regarding specimen preparation. We thank Dr. Stephen Scally for his input during the course of this work. This work was supported by the CIFAR Azrieli Global Scholar program (JPJ), the Ontario Early Researcher Award program (JPJ), the Canada Research Chair program (JPJ and JLR), and the Canadian Institutes of Health Research (RP). I.K. was supported by a SickKids Restracomp Fellowship, E.T. by a CIHR Canada Graduate Scholarship, and A.S. by an NSERC Canada Graduate Scholarship and a SickKids Restracomp Scholarship. This research was enabled in part by support provided by Compute Ontario (<ext-link ext-link-type="uri" xlink:href="https://computeontario.ca/">https://computeontario.ca/</ext-link>) and Compute Canada (<ext-link ext-link-type="uri" xlink:href="https://www.computecanada.ca/">https://www.computecanada.ca/</ext-link>). The ITC and BLI instruments were accessed at the Structural and Biophysical Core Facility, The Hospital for Sick Children, supported by the Canada Foundation for Innovation and Ontario Research Fund. CryoEM data was collected at the Toronto High Resolution High Throughput cryoEM facility, supported by the Canada Foundation for Innovation and Ontario Research Fund. X-ray diffraction experiments were performed at GM/CA@APS, which has been funded in whole or in part with federal funds from the National Cancer Institute (ACB-12002) and the National Institute of General Medical Sciences (AGM-12006). The Eiger 16M detector was funded by an NIH–Office of Research Infrastructure Programs High-End Instrumentation grant (1S10OD012289-01A1). This research used resources of the Advanced Photon Source, a U.S. Department of Energy (DOE) Office of Science user facility operated for the DOE Office of Science by Argonne National Laboratory under contract DE-AC02-06CH11357. X-ray diffraction experiments were also performed at the National Synchrotron Light Source II, a U.S. Department of Energy (DOE) Office of Science User Facility operated for the DOE Office of Science by Brookhaven National Laboratory under Contract No. DE-SC0012704. The Life Science Biomedical Technology Research resource is primarily supported by the National Institute of Health, National Institute of General Medical Sciences (NIGMS) through a Biomedical Technology Research Resource P41 grant (P41GM111244), and by the DOE Office of Biological and Environmental Research (KP1605010). The following reagent was obtained through BEI Resources, NIAID, NIH: Hybridoma 3D11 Anti-Plasmodium berghei 44-Kilodalton Sporozoite Surface Protein (Pb44), MRA-100, contributed by Victor Nussenzweig. X-ray crystallography and cryoEM data and structures are accessible from the Protein Data Bank and the Electron Microscopy Data Bank under PDB IDs 6X8P, 6X8Q, 6X8S, 6X8U and 6X87, and EMDB 22089, respectively.</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Formal analysis, Validation, Investigation, Visualization, Methodology, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con2"><p>Formal analysis, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con3"><p>Formal analysis, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con4"><p>Supervision, Funding acquisition, Validation, Visualization, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con5"><p>Supervision, Funding acquisition, Validation, Visualization, Methodology, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con6"><p>Conceptualization, Supervision, Funding acquisition, Validation, Visualization, Methodology, Writing - original draft, Project administration, Writing - review and editing</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Hydrogen-bonding propensities from simulations of peptides in solution.</title><p>(<bold>A</bold>) Hydrogen-bonding propensity for each simulated motif and lifetime of each β-turn for the four PfCSP-derived peptides. (<bold>B</bold>) Hydrogen-bonding propensity for each simulated motif and lifetime of each β-turn for the four PbCSP-derived peptides.</p></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-59018-supp1-v1.docx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>Table of contacts between 3D11 Fab and PbCSP peptides.</title><p>Rows are shaded according to the number of times interactions are observed between all four crystal structures, summed in the final column.</p></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-59018-supp2-v1.docx"/></supplementary-material><supplementary-material id="supp3"><label>Supplementary file 3.</label><caption><title>Table of contacts between one of the 3D11 Fabs and PbCSP in the cryoEM.</title></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-59018-supp3-v1.docx"/></supplementary-material><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="pdf" mimetype="application" xlink:href="elife-59018-transrepform-v1.pdf"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>X-ray crystallography and cryoEM data and structures have been deposited to the Protein Data Bank and the Electron Microscopy Data Bank.</p><p>The following datasets were generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Thai</surname><given-names>E</given-names></name><name><surname>Julien</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2020">2020</year><data-title>Crystal structure of 3D11 Fab in complex with Plasmodium berghei circumsporozoite protein PAPP peptide</data-title><source>RCSB Protein Data Bank</source><pub-id assigning-authority="PDB" pub-id-type="accession" xlink:href="http://www.rcsb.org/structure/6X8Q">6X8Q</pub-id></element-citation></p><p><element-citation id="dataset2" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Thai</surname><given-names>E</given-names></name><name><surname>Julien</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2020">2020</year><data-title>Crystal structure of 3D11 Fab in complex with Plasmodium berghei circumsporozoite protein NAND peptide</data-title><source>RCSB Protein Data Bank</source><pub-id assigning-authority="PDB" pub-id-type="accession" xlink:href="http://www.rcsb.org/structure/6X8S">6X8S</pub-id></element-citation></p><p><element-citation id="dataset3" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Thai</surname><given-names>E</given-names></name><name><surname>Julien</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2020">2020</year><data-title>Crystal structure of 3D11 Fab in complex with Plasmodium berghei circumsporozoite protein NPND peptide</data-title><source>RCSB Protein Data Bank</source><pub-id assigning-authority="PDB" pub-id-type="accession" xlink:href="http://www.rcsb.org/structure/6X8P">6X8P</pub-id></element-citation></p><p><element-citation id="dataset4" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Thai</surname><given-names>E</given-names></name><name><surname>Julien</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2020">2020</year><data-title>Crystal structure of 3D11 Fab in complex with Plasmodium berghei circumsporozoite protein Mixed peptide</data-title><source>RCSB Protein Data Bank</source><pub-id assigning-authority="PDB" pub-id-type="accession" xlink:href="http://www.rcsb.org/structure/6X8U">6X8U</pub-id></element-citation></p><p><element-citation id="dataset5" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Kucharska</surname><given-names>I</given-names></name><name><surname>Thai</surname><given-names>E</given-names></name><name><surname>Rubinstein</surname><given-names>J</given-names></name><name><surname>Julien</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2020">2020</year><data-title>CryoEM structure of the Plasmodium berghei circumsporozoite protein in complex with inhibitory mouse antibody 3D11</data-title><source>RCSB Protein Data Bank</source><pub-id assigning-authority="PDB" pub-id-type="accession" xlink:href="http://www.rcsb.org/structure/6X87">6X87</pub-id></element-citation></p><p><element-citation id="dataset6" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Kucharska</surname><given-names>I</given-names></name><name><surname>Thai</surname><given-names>E</given-names></name><name><surname>Rubinstein</surname><given-names>J</given-names></name><name><surname>Julien</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2020">2020</year><data-title>CryoEM structure of the Plasmodium berghei circumsporozoite protein in complex with inhibitory mouse antibody 3D11</data-title><source>Electron Microscopy Data Bank</source><pub-id assigning-authority="EMDB" pub-id-type="accession" xlink:href="http://www.ebi.ac.uk/pdbe/entry/emdb/EMD-22089">22089</pub-id></element-citation></p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abraham</surname> <given-names>MJ</given-names></name><name><surname>Murtola</surname> <given-names>T</given-names></name><name><surname>Schulz</surname> <given-names>R</given-names></name><name><surname>Páll</surname> <given-names>S</given-names></name><name><surname>Smith</surname> <given-names>JC</given-names></name><name><surname>Hess</surname> <given-names>B</given-names></name><name><surname>Lindahl</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>GROMACS: high performance molecular simulations through multi-level parallelism from laptops to supercomputers</article-title><source>SoftwareX</source><volume>1-2</volume><fpage>19</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1016/j.softx.2015.06.001</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname> <given-names>PD</given-names></name><name><surname>Afonine</surname> <given-names>PV</given-names></name><name><surname>Bunkóczi</surname> <given-names>G</given-names></name><name><surname>Chen</surname> <given-names>VB</given-names></name><name><surname>Davis</surname> <given-names>IW</given-names></name><name><surname>Echols</surname> <given-names>N</given-names></name><name><surname>Headd</surname> <given-names>JJ</given-names></name><name><surname>Hung</surname> <given-names>LW</given-names></name><name><surname>Kapral</surname> <given-names>GJ</given-names></name><name><surname>Grosse-Kunstleve</surname> <given-names>RW</given-names></name><name><surname>McCoy</surname> <given-names>AJ</given-names></name><name><surname>Moriarty</surname> <given-names>NW</given-names></name><name><surname>Oeffner</surname> <given-names>R</given-names></name><name><surname>Read</surname> <given-names>RJ</given-names></name><name><surname>Richardson</surname> <given-names>DC</given-names></name><name><surname>Richardson</surname> <given-names>JS</given-names></name><name><surname>Terwilliger</surname> <given-names>TC</given-names></name><name><surname>Zwart</surname> <given-names>PH</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title><italic>PHENIX</italic>: a comprehensive Python-based system for macromolecular structure solution</article-title><source>Acta Crystallographica Section D Biological Crystallography</source><volume>66</volume><fpage>213</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1107/S0907444909052925</pub-id><pub-id pub-id-type="pmid">20124702</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adepoju</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>RTS,S malaria vaccine pilots in three african countries</article-title><source>The Lancet</source><volume>393</volume><elocation-id>1685</elocation-id><pub-id pub-id-type="doi">10.1016/S0140-6736(19)30937-7</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berendsen</surname> <given-names>HJC</given-names></name><name><surname>van der Spoel</surname> <given-names>D</given-names></name><name><surname>van Drunen</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>GROMACS: a message-passing parallel molecular dynamics implementation</article-title><source>Computer Physics Communications</source><volume>91</volume><fpage>43</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1016/0010-4655(95)00042-E</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bernedo-Navarro</surname> <given-names>R</given-names></name><name><surname>Romão</surname> <given-names>E</given-names></name><name><surname>Yano</surname> <given-names>T</given-names></name><name><surname>Pinto</surname> <given-names>J</given-names></name><name><surname>De Greve</surname> <given-names>H</given-names></name><name><surname>Sterckx</surname> <given-names>Y</given-names></name><name><surname>Muyldermans</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Structural basis for the specific neutralization of Stx2a with a camelid single domain antibody fragment</article-title><source>Toxins</source><volume>10</volume><elocation-id>108</elocation-id><pub-id pub-id-type="doi">10.3390/toxins10030108</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Best</surname> <given-names>RB</given-names></name><name><surname>Hummer</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Optimized molecular dynamics force fields applied to the helix-coil transition of polypeptides</article-title><source>The Journal of Physical Chemistry B</source><volume>113</volume><fpage>9004</fpage><lpage>9015</lpage><pub-id pub-id-type="doi">10.1021/jp901540t</pub-id><pub-id pub-id-type="pmid">19514729</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Best</surname> <given-names>RB</given-names></name><name><surname>Mittal</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Protein simulations with an optimized water model: cooperative Helix formation and Temperature-Induced unfolded state collapse</article-title><source>The Journal of Physical Chemistry. B</source><volume>114</volume><fpage>14916</fpage><lpage>14923</lpage><pub-id pub-id-type="doi">10.1021/jp108618d</pub-id><pub-id pub-id-type="pmid">21038907</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Booth</surname> <given-names>DS</given-names></name><name><surname>Avila-Sakar</surname> <given-names>A</given-names></name><name><surname>Cheng</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Visualizing proteins and macromolecular complexes by negative stain EM: from grid preparation to image acquisition</article-title><source>Journal of Visualized Experiments</source><volume>22</volume><elocation-id>3227</elocation-id><pub-id pub-id-type="doi">10.3791/3227</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cerami</surname> <given-names>C</given-names></name><name><surname>Frevert</surname> <given-names>U</given-names></name><name><surname>Sinnis</surname> <given-names>P</given-names></name><name><surname>Takacs</surname> <given-names>B</given-names></name><name><surname>Clavijo</surname> <given-names>P</given-names></name><name><surname>Santos</surname> <given-names>MJ</given-names></name><name><surname>Nussenzweig</surname> <given-names>V</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>The basolateral domain of the hepatocyte plasma membrane bears receptors for the circumsporozoite protein of <italic>Plasmodium falciparum</italic> sporozoites</article-title><source>Cell</source><volume>70</volume><fpage>1021</fpage><lpage>1033</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(92)90251-7</pub-id><pub-id pub-id-type="pmid">1326407</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>VB</given-names></name><name><surname>Arendall</surname> <given-names>WB</given-names></name><name><surname>Headd</surname> <given-names>JJ</given-names></name><name><surname>Keedy</surname> <given-names>DA</given-names></name><name><surname>Immormino</surname> <given-names>RM</given-names></name><name><surname>Kapral</surname> <given-names>GJ</given-names></name><name><surname>Murray</surname> <given-names>LW</given-names></name><name><surname>Richardson</surname> <given-names>JS</given-names></name><name><surname>Richardson</surname> <given-names>DC</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>MolProbity: all-atom structure validation for macromolecular crystallography</article-title><source>Acta Crystallographica Section D Biological Crystallography</source><volume>66</volume><fpage>12</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1107/S0907444909042073</pub-id><pub-id pub-id-type="pmid">20057044</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chenet</surname> <given-names>SM</given-names></name><name><surname>Tapia</surname> <given-names>LL</given-names></name><name><surname>Escalante</surname> <given-names>AA</given-names></name><name><surname>Durand</surname> <given-names>S</given-names></name><name><surname>Lucas</surname> <given-names>C</given-names></name><name><surname>Bacon</surname> <given-names>DJ</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Genetic diversity and population structure of genes encoding vaccine candidate antigens of plasmodium vivax</article-title><source>Malaria Journal</source><volume>11</volume><elocation-id>68</elocation-id><pub-id pub-id-type="doi">10.1186/1475-2875-11-68</pub-id><pub-id pub-id-type="pmid">22417572</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cochrane</surname> <given-names>AH</given-names></name><name><surname>Aikawa</surname> <given-names>M</given-names></name><name><surname>Jeng</surname> <given-names>M</given-names></name><name><surname>Nussenzweig</surname> <given-names>RS</given-names></name></person-group><year iso-8601-date="1976">1976</year><article-title>Antibody-induced ultrastructural changes of malarial sporozoites</article-title><source>Journal of Immunology</source><volume>116</volume><fpage>859</fpage><lpage>867</lpage><pub-id pub-id-type="pmid">815435</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cui</surname> <given-names>L</given-names></name><name><surname>Mharakurwa</surname> <given-names>S</given-names></name><name><surname>Ndiaye</surname> <given-names>D</given-names></name><name><surname>Rathod</surname> <given-names>PK</given-names></name><name><surname>Rosenthal</surname> <given-names>PJ</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Antimalarial drug resistance: literature review and activities and findings of the ICEMR network</article-title><source>The American Journal of Tropical Medicine and Hygiene</source><volume>93</volume><fpage>57</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.4269/ajtmh.15-0007</pub-id><pub-id pub-id-type="pmid">26259943</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dame</surname> <given-names>JB</given-names></name><name><surname>Williams</surname> <given-names>JL</given-names></name><name><surname>McCutchan</surname> <given-names>TF</given-names></name><name><surname>Weber</surname> <given-names>JL</given-names></name><name><surname>Wirtz</surname> <given-names>RA</given-names></name><name><surname>Hockmeyer</surname> <given-names>WT</given-names></name><name><surname>Maloy</surname> <given-names>WL</given-names></name><name><surname>Haynes</surname> <given-names>JD</given-names></name><name><surname>Schneider</surname> <given-names>I</given-names></name><name><surname>Roberts</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="1984">1984</year><article-title>Structure of the gene encoding the immunodominant surface antigen on the sporozoite of the human malaria parasite <italic>Plasmodium falciparum</italic></article-title><source>Science</source><volume>225</volume><fpage>593</fpage><lpage>599</lpage><pub-id pub-id-type="doi">10.1126/science.6204383</pub-id><pub-id pub-id-type="pmid">6204383</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Darden</surname> <given-names>T</given-names></name><name><surname>York</surname> <given-names>D</given-names></name><name><surname>Pedersen</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>Particle mesh Ewald: A<italic>n N</italic> ⋅log( <italic>N</italic> ) method for Ewald sums i<italic>n</italic> large systems</article-title><source>The Journal of Chemical Physics</source><volume>98</volume><fpage>10089</fpage><lpage>10092</lpage><pub-id pub-id-type="doi">10.1063/1.464397</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davies</surname> <given-names>DH</given-names></name><name><surname>Duffy</surname> <given-names>P</given-names></name><name><surname>Bodmer</surname> <given-names>JL</given-names></name><name><surname>Felgner</surname> <given-names>PL</given-names></name><name><surname>Doolan</surname> <given-names>DL</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Large screen approaches to identify novel malaria vaccine candidates</article-title><source>Vaccine</source><volume>33</volume><fpage>7496</fpage><lpage>7505</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2015.09.059</pub-id><pub-id pub-id-type="pmid">26428458</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davies</surname> <given-names>HM</given-names></name><name><surname>Nofal</surname> <given-names>SD</given-names></name><name><surname>McLaughlin</surname> <given-names>EJ</given-names></name><name><surname>Osborne</surname> <given-names>AR</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Repetitive sequences in malaria parasite proteins</article-title><source>FEMS Microbiology Reviews</source><volume>41</volume><fpage>923</fpage><lpage>940</lpage><pub-id pub-id-type="doi">10.1093/femsre/fux046</pub-id><pub-id pub-id-type="pmid">29077880</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Koning-Ward</surname> <given-names>TF</given-names></name><name><surname>Gilson</surname> <given-names>PR</given-names></name><name><surname>Crabb</surname> <given-names>BS</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Advances in molecular genetic systems in malaria</article-title><source>Nature Reviews Microbiology</source><volume>13</volume><fpage>373</fpage><lpage>387</lpage><pub-id pub-id-type="doi">10.1038/nrmicro3450</pub-id><pub-id pub-id-type="pmid">25978707</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Niz</surname> <given-names>M</given-names></name><name><surname>Heussler</surname> <given-names>VT</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Rodent malaria models: insights into human disease and parasite biology</article-title><source>Current Opinion in Microbiology</source><volume>46</volume><fpage>93</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1016/j.mib.2018.09.003</pub-id><pub-id pub-id-type="pmid">30317152</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dobaño</surname> <given-names>C</given-names></name><name><surname>Sanz</surname> <given-names>H</given-names></name><name><surname>Sorgho</surname> <given-names>H</given-names></name><name><surname>Dosoo</surname> <given-names>D</given-names></name><name><surname>Mpina</surname> <given-names>M</given-names></name><name><surname>Ubillos</surname> <given-names>I</given-names></name><name><surname>Aguilar</surname> <given-names>R</given-names></name><name><surname>Ford</surname> <given-names>T</given-names></name><name><surname>Díez-Padrisa</surname> <given-names>N</given-names></name><name><surname>Williams</surname> <given-names>NA</given-names></name><name><surname>Ayestaran</surname> <given-names>A</given-names></name><name><surname>Traore</surname> <given-names>O</given-names></name><name><surname>Nhabomba</surname> <given-names>AJ</given-names></name><name><surname>Jairoce</surname> <given-names>C</given-names></name><name><surname>Waitumbi</surname> <given-names>J</given-names></name><name><surname>Agnandji</surname> <given-names>ST</given-names></name><name><surname>Kariuki</surname> <given-names>S</given-names></name><name><surname>Abdulla</surname> <given-names>S</given-names></name><name><surname>Aponte</surname> <given-names>JJ</given-names></name><name><surname>Mordmüller</surname> <given-names>B</given-names></name><name><surname>Asante</surname> <given-names>KP</given-names></name><name><surname>Owusu-Agyei</surname> <given-names>S</given-names></name><name><surname>Tinto</surname> <given-names>H</given-names></name><name><surname>Campo</surname> <given-names>JJ</given-names></name><name><surname>Moncunill</surname> <given-names>G</given-names></name><name><surname>Gyan</surname> <given-names>B</given-names></name><name><surname>Valim</surname> <given-names>C</given-names></name><name><surname>Daubenberger</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Concentration and avidity of antibodies to different circumsporozoite epitopes correlate with RTS,S/AS01E malaria vaccine efficacy</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>2174</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-10195-z</pub-id><pub-id pub-id-type="pmid">31092823</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doolan</surname> <given-names>DL</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Plasmodium immunomics</article-title><source>International Journal for Parasitology</source><volume>41</volume><fpage>3</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1016/j.ijpara.2010.08.002</pub-id><pub-id pub-id-type="pmid">20816843</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Draper</surname> <given-names>SJ</given-names></name><name><surname>Sack</surname> <given-names>BK</given-names></name><name><surname>King</surname> <given-names>CR</given-names></name><name><surname>Nielsen</surname> <given-names>CM</given-names></name><name><surname>Rayner</surname> <given-names>JC</given-names></name><name><surname>Higgins</surname> <given-names>MK</given-names></name><name><surname>Long</surname> <given-names>CA</given-names></name><name><surname>Seder</surname> <given-names>RA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Malaria vaccines: recent advances and new horizons</article-title><source>Cell Host &amp; Microbe</source><volume>24</volume><fpage>43</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2018.06.008</pub-id><pub-id pub-id-type="pmid">30001524</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dyson</surname> <given-names>HJ</given-names></name><name><surname>Satterthwait</surname> <given-names>AC</given-names></name><name><surname>Lerner</surname> <given-names>RA</given-names></name><name><surname>Wright</surname> <given-names>PE</given-names></name></person-group><year iso-8601-date="1990">1990</year><article-title>Conformational preferences of synthetic peptides derived from the immunodominant site of the circumsporozoite protein of <italic>Plasmodium falciparum</italic> by 1H NMR</article-title><source>Biochemistry</source><volume>29</volume><fpage>7828</fpage><lpage>7837</lpage><pub-id pub-id-type="doi">10.1021/bi00486a008</pub-id><pub-id pub-id-type="pmid">2261440</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eichinger</surname> <given-names>DJ</given-names></name><name><surname>Arnot</surname> <given-names>DE</given-names></name><name><surname>Tam</surname> <given-names>JP</given-names></name><name><surname>Nussenzweig</surname> <given-names>V</given-names></name><name><surname>Enea</surname> <given-names>V</given-names></name></person-group><year iso-8601-date="1986">1986</year><article-title>Circumsporozoite protein of plasmodium berghei: gene cloning and identification of the immunodominant epitopes</article-title><source>Molecular and Cellular Biology</source><volume>6</volume><fpage>3965</fpage><lpage>3972</lpage><pub-id pub-id-type="doi">10.1128/MCB.6.11.3965</pub-id><pub-id pub-id-type="pmid">2432395</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Emsley</surname> <given-names>P</given-names></name><name><surname>Lohkamp</surname> <given-names>B</given-names></name><name><surname>Scott</surname> <given-names>WG</given-names></name><name><surname>Cowtan</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Features and development of <italic>coot</italic></article-title><source>Acta Crystallographica. Section D, Biological Crystallography</source><volume>66</volume><fpage>486</fpage><lpage>501</lpage><pub-id pub-id-type="doi">10.1107/S0907444910007493</pub-id><pub-id pub-id-type="pmid">20383002</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Essmann</surname> <given-names>U</given-names></name><name><surname>Perera</surname> <given-names>L</given-names></name><name><surname>Berkowitz</surname> <given-names>ML</given-names></name><name><surname>Darden</surname> <given-names>T</given-names></name><name><surname>Lee</surname> <given-names>H</given-names></name><name><surname>Pedersen</surname> <given-names>LG</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>A smooth particle mesh ewald method</article-title><source>The Journal of Chemical Physics</source><volume>103</volume><fpage>8577</fpage><lpage>8593</lpage><pub-id pub-id-type="doi">10.1063/1.470117</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frevert</surname> <given-names>U</given-names></name><name><surname>Sinnis</surname> <given-names>P</given-names></name><name><surname>Cerami</surname> <given-names>C</given-names></name><name><surname>Shreffler</surname> <given-names>W</given-names></name><name><surname>Takacs</surname> <given-names>B</given-names></name><name><surname>Nussenzweig</surname> <given-names>V</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>Malaria circumsporozoite protein binds to heparan sulfate proteoglycans associated with the surface membrane of hepatocytes</article-title><source>Journal of Experimental Medicine</source><volume>177</volume><fpage>1287</fpage><lpage>1298</lpage><pub-id pub-id-type="doi">10.1084/jem.177.5.1287</pub-id><pub-id pub-id-type="pmid">8478608</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghasparian</surname> <given-names>A</given-names></name><name><surname>Moehle</surname> <given-names>K</given-names></name><name><surname>Linden</surname> <given-names>A</given-names></name><name><surname>Robinson</surname> <given-names>JA</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Crystal structure of an NPNA-repeat motif from the circumsporozoite protein of the malaria parasite <italic>Plasmodium falciparum</italic></article-title><source>Chem. Commun.</source><volume>365</volume><fpage>174</fpage><lpage>176</lpage><pub-id pub-id-type="doi">10.1039/B510812H</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goddard</surname> <given-names>TD</given-names></name><name><surname>Huang</surname> <given-names>CC</given-names></name><name><surname>Meng</surname> <given-names>EC</given-names></name><name><surname>Pettersen</surname> <given-names>EF</given-names></name><name><surname>Couch</surname> <given-names>GS</given-names></name><name><surname>Morris</surname> <given-names>JH</given-names></name><name><surname>Ferrin</surname> <given-names>TE</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>UCSF ChimeraX: meeting modern challenges in visualization and analysis</article-title><source>Protein Science</source><volume>27</volume><fpage>14</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1002/pro.3235</pub-id><pub-id pub-id-type="pmid">28710774</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hall</surname> <given-names>BF</given-names></name><name><surname>Fauci</surname> <given-names>AS</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Malaria control, elimination, and eradication: the role of the evolving biomedical research agenda</article-title><source>The Journal of Infectious Diseases</source><volume>200</volume><fpage>1639</fpage><lpage>1643</lpage><pub-id pub-id-type="doi">10.1086/646611</pub-id><pub-id pub-id-type="pmid">19877843</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herrera</surname> <given-names>R</given-names></name><name><surname>Anderson</surname> <given-names>C</given-names></name><name><surname>Kumar</surname> <given-names>K</given-names></name><name><surname>Molina-Cruz</surname> <given-names>A</given-names></name><name><surname>Nguyen</surname> <given-names>V</given-names></name><name><surname>Burkhardt</surname> <given-names>M</given-names></name><name><surname>Reiter</surname> <given-names>K</given-names></name><name><surname>Shimp</surname> <given-names>R</given-names></name><name><surname>Howard</surname> <given-names>RF</given-names></name><name><surname>Srinivasan</surname> <given-names>P</given-names></name><name><surname>Nold</surname> <given-names>MJ</given-names></name><name><surname>Ragheb</surname> <given-names>D</given-names></name><name><surname>Shi</surname> <given-names>L</given-names></name><name><surname>DeCotiis</surname> <given-names>M</given-names></name><name><surname>Aebig</surname> <given-names>J</given-names></name><name><surname>Lambert</surname> <given-names>L</given-names></name><name><surname>Rausch</surname> <given-names>KM</given-names></name><name><surname>Muratova</surname> <given-names>O</given-names></name><name><surname>Jin</surname> <given-names>A</given-names></name><name><surname>Reed</surname> <given-names>SG</given-names></name><name><surname>Sinnis</surname> <given-names>P</given-names></name><name><surname>Barillas-Mury</surname> <given-names>C</given-names></name><name><surname>Duffy</surname> <given-names>PE</given-names></name><name><surname>MacDonald</surname> <given-names>NJ</given-names></name><name><surname>Narum</surname> <given-names>DL</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Reversible conformational change in the <italic>Plasmodium falciparum</italic> circumsporozoite protein masks its adhesion domains</article-title><source>Infection and Immunity</source><volume>83</volume><fpage>3771</fpage><lpage>3780</lpage><pub-id pub-id-type="doi">10.1128/IAI.02676-14</pub-id><pub-id pub-id-type="pmid">26169272</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hess</surname> <given-names>B</given-names></name><name><surname>Bekker</surname> <given-names>H</given-names></name><name><surname>Berendsen</surname> <given-names>HJC</given-names></name><name><surname>Fraaije</surname> <given-names>JGEM</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>LINCS: a linear constraint solver for molecular simulations</article-title><source>Journal of Computational Chemistry</source><volume>18</volume><fpage>1463</fpage><lpage>1472</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1096-987X(199709)18:12&lt;1463::AID-JCC4&gt;3.0.CO;2-H</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hess</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>P-LINCS: A Parallel Linear Constraint Solver for Molecular Simulation</article-title><source>Journal of Chemical Theory and Computation</source><volume>4</volume><fpage>116</fpage><lpage>122</lpage><pub-id pub-id-type="doi">10.1021/ct700200b</pub-id><pub-id pub-id-type="pmid">26619985</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoover</surname> <given-names>WG</given-names></name></person-group><year iso-8601-date="1985">1985</year><article-title>Canonical dynamics: equilibrium phase-space distributions</article-title><source>Physical Review A</source><volume>31</volume><fpage>1695</fpage><lpage>1697</lpage><pub-id pub-id-type="doi">10.1103/PhysRevA.31.1695</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Humphrey</surname> <given-names>W</given-names></name><name><surname>Dalke</surname> <given-names>A</given-names></name><name><surname>Schulten</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>VMD: Visual molecular dynamics</article-title><source>Journal of Molecular Graphics</source><volume>14</volume><fpage>33</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1016/0263-7855(96)00018-5</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hunter</surname> <given-names>JD</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Matplotlib: A 2D Graphics Environment</article-title><source>Computing in Science &amp; Engineering</source><volume>9</volume><fpage>90</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1109/MCSE.2007.55</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Illingworth</surname> <given-names>JJ</given-names></name><name><surname>Alanine</surname> <given-names>DG</given-names></name><name><surname>Brown</surname> <given-names>R</given-names></name><name><surname>Marshall</surname> <given-names>JM</given-names></name><name><surname>Bartlett</surname> <given-names>HE</given-names></name><name><surname>Silk</surname> <given-names>SE</given-names></name><name><surname>Labbé</surname> <given-names>GM</given-names></name><name><surname>Quinkert</surname> <given-names>D</given-names></name><name><surname>Cho</surname> <given-names>JS</given-names></name><name><surname>Wendler</surname> <given-names>JP</given-names></name><name><surname>Pattinson</surname> <given-names>DJ</given-names></name><name><surname>Barfod</surname> <given-names>L</given-names></name><name><surname>Douglas</surname> <given-names>AD</given-names></name><name><surname>Shea</surname> <given-names>MW</given-names></name><name><surname>Wright</surname> <given-names>KE</given-names></name><name><surname>de Cassan</surname> <given-names>SC</given-names></name><name><surname>Higgins</surname> <given-names>MK</given-names></name><name><surname>Draper</surname> <given-names>SJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Functional comparison of Blood-Stage <italic>Plasmodium falciparum</italic> Malaria Vaccine Candidate Antigens</article-title><source>Frontiers in Immunology</source><volume>10</volume><elocation-id>1254</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2019.01254</pub-id><pub-id pub-id-type="pmid">31214195</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Imkeller</surname> <given-names>K</given-names></name><name><surname>Scally</surname> <given-names>SW</given-names></name><name><surname>Bosch</surname> <given-names>A</given-names></name><name><surname>Martí</surname> <given-names>GP</given-names></name><name><surname>Costa</surname> <given-names>G</given-names></name><name><surname>Triller</surname> <given-names>G</given-names></name><name><surname>Murugan</surname> <given-names>R</given-names></name><name><surname>Renna</surname> <given-names>V</given-names></name><name><surname>Jumaa</surname> <given-names>H</given-names></name><name><surname>Kremsner</surname> <given-names>PG</given-names></name><name><surname>Sim</surname> <given-names>BKL</given-names></name><name><surname>Hoffman</surname> <given-names>SL</given-names></name><name><surname>Mordmüller</surname> <given-names>B</given-names></name><name><surname>Levashina</surname> <given-names>EA</given-names></name><name><surname>Julien</surname> <given-names>JP</given-names></name><name><surname>Wardemann</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Antihomotypic affinity maturation improves human B cell responses against a repetitive epitope</article-title><source>Science</source><volume>360</volume><fpage>1358</fpage><lpage>1362</lpage><pub-id pub-id-type="doi">10.1126/science.aar5304</pub-id><pub-id pub-id-type="pmid">29880723</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jorgensen</surname> <given-names>WL</given-names></name><name><surname>Chandrasekhar</surname> <given-names>J</given-names></name><name><surname>Madura</surname> <given-names>JD</given-names></name><name><surname>Impey</surname> <given-names>RW</given-names></name><name><surname>Klein</surname> <given-names>ML</given-names></name></person-group><year iso-8601-date="1983">1983</year><article-title>Comparison of simple potential functions for simulating liquid water</article-title><source>The Journal of Chemical Physics</source><volume>79</volume><fpage>926</fpage><lpage>935</lpage><pub-id pub-id-type="doi">10.1063/1.445869</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Julien</surname> <given-names>JP</given-names></name><name><surname>Wardemann</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Antibodies against <italic>Plasmodium falciparum</italic> malaria at the molecular level</article-title><source>Nature Reviews Immunology</source><volume>19</volume><fpage>761</fpage><lpage>775</lpage><pub-id pub-id-type="doi">10.1038/s41577-019-0209-5</pub-id><pub-id pub-id-type="pmid">31462718</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kabsch</surname> <given-names>W</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>XDS</article-title><source>Acta Crystallographica. Section D, Biological Crystallography</source><volume>66</volume><fpage>125</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1107/S0907444909047337</pub-id><pub-id pub-id-type="pmid">20124692</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kisalu</surname> <given-names>NK</given-names></name><name><surname>Idris</surname> <given-names>AH</given-names></name><name><surname>Weidle</surname> <given-names>C</given-names></name><name><surname>Flores-Garcia</surname> <given-names>Y</given-names></name><name><surname>Flynn</surname> <given-names>BJ</given-names></name><name><surname>Sack</surname> <given-names>BK</given-names></name><name><surname>Murphy</surname> <given-names>S</given-names></name><name><surname>Schön</surname> <given-names>A</given-names></name><name><surname>Freire</surname> <given-names>E</given-names></name><name><surname>Francica</surname> <given-names>JR</given-names></name><name><surname>Miller</surname> <given-names>AB</given-names></name><name><surname>Gregory</surname> <given-names>J</given-names></name><name><surname>March</surname> <given-names>S</given-names></name><name><surname>Liao</surname> <given-names>HX</given-names></name><name><surname>Haynes</surname> <given-names>BF</given-names></name><name><surname>Wiehe</surname> <given-names>K</given-names></name><name><surname>Trama</surname> <given-names>AM</given-names></name><name><surname>Saunders</surname> <given-names>KO</given-names></name><name><surname>Gladden</surname> <given-names>MA</given-names></name><name><surname>Monroe</surname> <given-names>A</given-names></name><name><surname>Bonsignori</surname> <given-names>M</given-names></name><name><surname>Kanekiyo</surname> <given-names>M</given-names></name><name><surname>Wheatley</surname> <given-names>AK</given-names></name><name><surname>McDermott</surname> <given-names>AB</given-names></name><name><surname>Farney</surname> <given-names>SK</given-names></name><name><surname>Chuang</surname> <given-names>GY</given-names></name><name><surname>Zhang</surname> <given-names>B</given-names></name><name><surname>Kc</surname> <given-names>N</given-names></name><name><surname>Chakravarty</surname> <given-names>S</given-names></name><name><surname>Kwong</surname> <given-names>PD</given-names></name><name><surname>Sinnis</surname> <given-names>P</given-names></name><name><surname>Bhatia</surname> <given-names>SN</given-names></name><name><surname>Kappe</surname> <given-names>SHI</given-names></name><name><surname>Sim</surname> <given-names>BKL</given-names></name><name><surname>Hoffman</surname> <given-names>SL</given-names></name><name><surname>Zavala</surname> <given-names>F</given-names></name><name><surname>Pancera</surname> <given-names>M</given-names></name><name><surname>Seder</surname> <given-names>RA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite</article-title><source>Nature Medicine</source><volume>24</volume><fpage>408</fpage><lpage>416</lpage><pub-id pub-id-type="doi">10.1038/nm.4512</pub-id><pub-id pub-id-type="pmid">29554083</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krissinel</surname> <given-names>E</given-names></name><name><surname>Henrick</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Inference of macromolecular assemblies from crystalline state</article-title><source>Journal of Molecular Biology</source><volume>372</volume><fpage>774</fpage><lpage>797</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2007.05.022</pub-id><pub-id pub-id-type="pmid">17681537</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lindorff-Larsen</surname> <given-names>K</given-names></name><name><surname>Maragakis</surname> <given-names>P</given-names></name><name><surname>Piana</surname> <given-names>S</given-names></name><name><surname>Eastwood</surname> <given-names>MP</given-names></name><name><surname>Dror</surname> <given-names>RO</given-names></name><name><surname>Shaw</surname> <given-names>DE</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Systematic validation of protein force fields against experimental data</article-title><source>PLOS ONE</source><volume>7</volume><elocation-id>e32131</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0032131</pub-id><pub-id pub-id-type="pmid">22384157</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lover</surname> <given-names>AA</given-names></name><name><surname>Baird</surname> <given-names>JK</given-names></name><name><surname>Gosling</surname> <given-names>R</given-names></name><name><surname>Price</surname> <given-names>RN</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Malaria elimination: time to target all species</article-title><source>The American Journal of Tropical Medicine and Hygiene</source><volume>99</volume><fpage>17</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.4269/ajtmh.17-0869</pub-id><pub-id pub-id-type="pmid">29761762</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ly</surname> <given-names>A</given-names></name><name><surname>Hansen</surname> <given-names>DS</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Development of B cell memory in malaria</article-title><source>Frontiers in Immunology</source><volume>10</volume><elocation-id>559</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2019.00559</pub-id><pub-id pub-id-type="pmid">31001244</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacKerell</surname> <given-names>AD</given-names></name><name><surname>Bashford</surname> <given-names>D</given-names></name><name><surname>Bellott</surname> <given-names>M</given-names></name><name><surname>Dunbrack</surname> <given-names>RL</given-names></name><name><surname>Evanseck</surname> <given-names>JD</given-names></name><name><surname>Field</surname> <given-names>MJ</given-names></name><name><surname>Fischer</surname> <given-names>S</given-names></name><name><surname>Gao</surname> <given-names>J</given-names></name><name><surname>Guo</surname> <given-names>H</given-names></name><name><surname>Ha</surname> <given-names>S</given-names></name><name><surname>Joseph-McCarthy</surname> <given-names>D</given-names></name><name><surname>Kuchnir</surname> <given-names>L</given-names></name><name><surname>Kuczera</surname> <given-names>K</given-names></name><name><surname>Lau</surname> <given-names>FTK</given-names></name><name><surname>Mattos</surname> <given-names>C</given-names></name><name><surname>Michnick</surname> <given-names>S</given-names></name><name><surname>Ngo</surname> <given-names>T</given-names></name><name><surname>Nguyen</surname> <given-names>DT</given-names></name><name><surname>Prodhom</surname> <given-names>B</given-names></name><name><surname>Reiher</surname> <given-names>WE</given-names></name><name><surname>Roux</surname> <given-names>B</given-names></name><name><surname>Schlenkrich</surname> <given-names>M</given-names></name><name><surname>Smith</surname> <given-names>JC</given-names></name><name><surname>Stote</surname> <given-names>R</given-names></name><name><surname>Straub</surname> <given-names>J</given-names></name><name><surname>Watanabe</surname> <given-names>M</given-names></name><name><surname>Wiórkiewicz-Kuczera</surname> <given-names>J</given-names></name><name><surname>Yin</surname> <given-names>D</given-names></name><name><surname>Karplus</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>All-Atom Empirical Potential for Molecular Modeling and Dynamics Studies of Proteins <sup>†</sup></article-title><source>The Journal of Physical Chemistry B</source><volume>102</volume><fpage>3586</fpage><lpage>3616</lpage><pub-id pub-id-type="doi">10.1021/jp973084f</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marr</surname> <given-names>CR</given-names></name><name><surname>Benlekbir</surname> <given-names>S</given-names></name><name><surname>Rubinstein</surname> <given-names>JL</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Fabrication of carbon films with ∼500nm holes for cryo-EM with a direct detector device</article-title><source>Journal of Structural Biology</source><volume>185</volume><fpage>42</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1016/j.jsb.2013.11.002</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCall</surname> <given-names>MBB</given-names></name><name><surname>Kremsner</surname> <given-names>PG</given-names></name><name><surname>Mordmüller</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Correlating efficacy and immunogenicity in malaria vaccine trials</article-title><source>Seminars in Immunology</source><volume>39</volume><fpage>52</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1016/j.smim.2018.08.002</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCoy</surname> <given-names>AJ</given-names></name><name><surname>Grosse-Kunstleve</surname> <given-names>RW</given-names></name><name><surname>Adams</surname> <given-names>PD</given-names></name><name><surname>Winn</surname> <given-names>MD</given-names></name><name><surname>Storoni</surname> <given-names>LC</given-names></name><name><surname>Read</surname> <given-names>RJ</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title><italic>Phaser</italic> crystallographic software</article-title><source>Journal of Applied Crystallography</source><volume>40</volume><fpage>658</fpage><lpage>674</lpage><pub-id pub-id-type="doi">10.1107/S0021889807021206</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ménard</surname> <given-names>R</given-names></name><name><surname>Sultan</surname> <given-names>AA</given-names></name><name><surname>Cortes</surname> <given-names>C</given-names></name><name><surname>Altszuler</surname> <given-names>R</given-names></name><name><surname>van Dijk</surname> <given-names>MR</given-names></name><name><surname>Janse</surname> <given-names>CJ</given-names></name><name><surname>Waters</surname> <given-names>AP</given-names></name><name><surname>Nussenzweig</surname> <given-names>RS</given-names></name><name><surname>Nussenzweig</surname> <given-names>V</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Circumsporozoite protein is required for development of malaria sporozoites in mosquitoes</article-title><source>Nature</source><volume>385</volume><fpage>336</fpage><lpage>340</lpage><pub-id pub-id-type="doi">10.1038/385336a0</pub-id><pub-id pub-id-type="pmid">9002517</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mendes</surname> <given-names>TAO</given-names></name><name><surname>Lobo</surname> <given-names>FP</given-names></name><name><surname>Rodrigues</surname> <given-names>TS</given-names></name><name><surname>Rodrigues-Luiz</surname> <given-names>GF</given-names></name><name><surname>daRocha</surname> <given-names>WD</given-names></name><name><surname>Fujiwara</surname> <given-names>RT</given-names></name><name><surname>Teixeira</surname> <given-names>SMR</given-names></name><name><surname>Bartholomeu</surname> <given-names>DC</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Repeat-Enriched Proteins Are Related to Host Cell Invasion and Immune Evasion in Parasitic Protozoa</article-title><source>Molecular Biology and Evolution</source><volume>30</volume><fpage>951</fpage><lpage>963</lpage><pub-id pub-id-type="doi">10.1093/molbev/mst001</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mishra</surname> <given-names>S</given-names></name><name><surname>Nussenzweig</surname> <given-names>RS</given-names></name><name><surname>Nussenzweig</surname> <given-names>V</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Antibodies to plasmodium circumsporozoite protein (CSP) inhibit sporozoite's cell traversal activity</article-title><source>Journal of Immunological Methods</source><volume>377</volume><fpage>47</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1016/j.jim.2012.01.009</pub-id><pub-id pub-id-type="pmid">22306356</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morin</surname> <given-names>A</given-names></name><name><surname>Eisenbraun</surname> <given-names>B</given-names></name><name><surname>Key</surname> <given-names>J</given-names></name><name><surname>Sanschagrin</surname> <given-names>PC</given-names></name><name><surname>Timony</surname> <given-names>MA</given-names></name><name><surname>Ottaviano</surname> <given-names>M</given-names></name><name><surname>Sliz</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Collaboration gets the most out of software</article-title><source>eLife</source><volume>2</volume><elocation-id>e01456</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.01456</pub-id><pub-id pub-id-type="pmid">24040512</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murugan</surname> <given-names>R</given-names></name><name><surname>Buchauer</surname> <given-names>L</given-names></name><name><surname>Triller</surname> <given-names>G</given-names></name><name><surname>Kreschel</surname> <given-names>C</given-names></name><name><surname>Costa</surname> <given-names>G</given-names></name><name><surname>Pidelaserra Martí</surname> <given-names>G</given-names></name><name><surname>Imkeller</surname> <given-names>K</given-names></name><name><surname>Busse</surname> <given-names>CE</given-names></name><name><surname>Chakravarty</surname> <given-names>S</given-names></name><name><surname>Sim</surname> <given-names>BKL</given-names></name><name><surname>Hoffman</surname> <given-names>SL</given-names></name><name><surname>Levashina</surname> <given-names>EA</given-names></name><name><surname>Kremsner</surname> <given-names>PG</given-names></name><name><surname>Mordmüller</surname> <given-names>B</given-names></name><name><surname>Höfer</surname> <given-names>T</given-names></name><name><surname>Wardemann</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Clonal selection drives protective memory B cell responses in controlled human malaria infection</article-title><source>Science Immunology</source><volume>3</volume><elocation-id>eaap8029</elocation-id><pub-id pub-id-type="doi">10.1126/sciimmunol.aap8029</pub-id><pub-id pub-id-type="pmid">29453292</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murugan</surname> <given-names>R</given-names></name><name><surname>Scally</surname> <given-names>SW</given-names></name><name><surname>Costa</surname> <given-names>G</given-names></name><name><surname>Mustafa</surname> <given-names>G</given-names></name><name><surname>Thai</surname> <given-names>E</given-names></name><name><surname>Decker</surname> <given-names>T</given-names></name><name><surname>Bosch</surname> <given-names>A</given-names></name><name><surname>Prieto</surname> <given-names>K</given-names></name><name><surname>Levashina</surname> <given-names>EA</given-names></name><name><surname>Julien</surname> <given-names>JP</given-names></name><name><surname>Wardemann</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Evolution of protective human antibodies against <italic>Plasmodium falciparum</italic> circumsporozoite protein repeat motifs</article-title><source>Nature Medicine</source><volume>26</volume><fpage>1135</fpage><lpage>1145</lpage><pub-id pub-id-type="doi">10.1038/s41591-020-0881-9</pub-id><pub-id pub-id-type="pmid">32451496</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nosé</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="1984">1984</year><article-title>A unified formulation of the constant temperature molecular dynamics methods</article-title><source>The Journal of Chemical Physics</source><volume>81</volume><fpage>511</fpage><lpage>519</lpage><pub-id pub-id-type="doi">10.1063/1.447334</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nussenzweig</surname> <given-names>RS</given-names></name><name><surname>Nussenzweig</surname> <given-names>V</given-names></name></person-group><year iso-8601-date="1984">1984</year><article-title>Development of sporozoite vaccines</article-title><source>Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences</source><volume>307</volume><fpage>117</fpage><lpage>128</lpage><pub-id pub-id-type="doi">10.1098/rstb.1984.0113</pub-id><pub-id pub-id-type="pmid">6084251</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olotu</surname> <given-names>A</given-names></name><name><surname>Fegan</surname> <given-names>G</given-names></name><name><surname>Wambua</surname> <given-names>J</given-names></name><name><surname>Nyangweso</surname> <given-names>G</given-names></name><name><surname>Leach</surname> <given-names>A</given-names></name><name><surname>Lievens</surname> <given-names>M</given-names></name><name><surname>Kaslow</surname> <given-names>DC</given-names></name><name><surname>Njuguna</surname> <given-names>P</given-names></name><name><surname>Marsh</surname> <given-names>K</given-names></name><name><surname>Bejon</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Seven-Year Efficacy of RTS,S/AS01 Malaria Vaccine among Young African Children</article-title><source>New England Journal of Medicine</source><volume>374</volume><fpage>2519</fpage><lpage>2529</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1515257</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oyen</surname> <given-names>D</given-names></name><name><surname>Torres</surname> <given-names>JL</given-names></name><name><surname>Wille-Reece</surname> <given-names>U</given-names></name><name><surname>Ockenhouse</surname> <given-names>CF</given-names></name><name><surname>Emerling</surname> <given-names>D</given-names></name><name><surname>Glanville</surname> <given-names>J</given-names></name><name><surname>Volkmuth</surname> <given-names>W</given-names></name><name><surname>Flores-Garcia</surname> <given-names>Y</given-names></name><name><surname>Zavala</surname> <given-names>F</given-names></name><name><surname>Ward</surname> <given-names>AB</given-names></name><name><surname>King</surname> <given-names>CR</given-names></name><name><surname>Wilson</surname> <given-names>IA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Structural basis for antibody recognition of the NANP repeats in <italic>Plasmodium falciparum</italic> circumsporozoite protein</article-title><source>PNAS</source><volume>114</volume><fpage>E10438</fpage><lpage>E10445</lpage><pub-id pub-id-type="doi">10.1073/pnas.1715812114</pub-id><pub-id pub-id-type="pmid">29138320</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oyen</surname> <given-names>D</given-names></name><name><surname>Torres</surname> <given-names>JL</given-names></name><name><surname>Cottrell</surname> <given-names>CA</given-names></name><name><surname>Richter King</surname> <given-names>C</given-names></name><name><surname>Wilson</surname> <given-names>IA</given-names></name><name><surname>Ward</surname> <given-names>AB</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Cryo-EM structure of <italic>P. falciparum</italic> circumsporozoite protein with a vaccine-elicited antibody is stabilized by somatically mutated inter-Fab contacts</article-title><source>Science Advances</source><volume>4</volume><elocation-id>eaau8529</elocation-id><pub-id pub-id-type="doi">10.1126/sciadv.aau8529</pub-id><pub-id pub-id-type="pmid">30324137</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parrinello</surname> <given-names>M</given-names></name><name><surname>Rahman</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="1981">1981</year><article-title>Polymorphic transitions in single crystals: a new molecular dynamics method</article-title><source>Journal of Applied Physics</source><volume>52</volume><fpage>7182</fpage><lpage>7190</lpage><pub-id pub-id-type="doi">10.1063/1.328693</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patra</surname> <given-names>AP</given-names></name><name><surname>Sharma</surname> <given-names>S</given-names></name><name><surname>Ainavarapu</surname> <given-names>SR</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Force spectroscopy of the <italic>Plasmodium falciparum</italic> Vaccine Candidate Circumsporozoite Protein Suggests a Mechanically Pliable Repeat Region</article-title><source>Journal of Biological Chemistry</source><volume>292</volume><fpage>2110</fpage><lpage>2119</lpage><pub-id pub-id-type="doi">10.1074/jbc.M116.754796</pub-id><pub-id pub-id-type="pmid">28031457</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pettersen</surname> <given-names>EF</given-names></name><name><surname>Goddard</surname> <given-names>TD</given-names></name><name><surname>Huang</surname> <given-names>CC</given-names></name><name><surname>Couch</surname> <given-names>GS</given-names></name><name><surname>Greenblatt</surname> <given-names>DM</given-names></name><name><surname>Meng</surname> <given-names>EC</given-names></name><name><surname>Ferrin</surname> <given-names>TE</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>UCSF chimera--a visualization system for exploratory research and analysis</article-title><source>Journal of Computational Chemistry</source><volume>25</volume><fpage>1605</fpage><lpage>1612</lpage><pub-id pub-id-type="doi">10.1002/jcc.20084</pub-id><pub-id pub-id-type="pmid">15264254</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pholcharee</surname> <given-names>T</given-names></name><name><surname>Oyen</surname> <given-names>D</given-names></name><name><surname>Torres</surname> <given-names>JL</given-names></name><name><surname>Flores-Garcia</surname> <given-names>Y</given-names></name><name><surname>Martin</surname> <given-names>GM</given-names></name><name><surname>González-Páez</surname> <given-names>GE</given-names></name><name><surname>Emerling</surname> <given-names>D</given-names></name><name><surname>Volkmuth</surname> <given-names>W</given-names></name><name><surname>Locke</surname> <given-names>E</given-names></name><name><surname>King</surname> <given-names>CR</given-names></name><name><surname>Zavala</surname> <given-names>F</given-names></name><name><surname>Ward</surname> <given-names>AB</given-names></name><name><surname>Wilson</surname> <given-names>IA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Diverse antibody responses to conserved structural motifs in <italic>Plasmodium falciparum</italic> circumsporozoite protein</article-title><source>Journal of Molecular Biology</source><volume>432</volume><fpage>1048</fpage><lpage>1063</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2019.12.029</pub-id><pub-id pub-id-type="pmid">31883801</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piana</surname> <given-names>S</given-names></name><name><surname>Lindorff-Larsen</surname> <given-names>K</given-names></name><name><surname>Shaw</surname> <given-names>DE</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>How robust are protein folding simulations with respect to force field parameterization?</article-title><source>Biophysical Journal</source><volume>100</volume><fpage>L47</fpage><lpage>L49</lpage><pub-id pub-id-type="doi">10.1016/j.bpj.2011.03.051</pub-id><pub-id pub-id-type="pmid">21539772</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Plassmeyer</surname> <given-names>ML</given-names></name><name><surname>Reiter</surname> <given-names>K</given-names></name><name><surname>Shimp</surname> <given-names>RL</given-names></name><name><surname>Kotova</surname> <given-names>S</given-names></name><name><surname>Smith</surname> <given-names>PD</given-names></name><name><surname>Hurt</surname> <given-names>DE</given-names></name><name><surname>House</surname> <given-names>B</given-names></name><name><surname>Zou</surname> <given-names>X</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Hickman</surname> <given-names>M</given-names></name><name><surname>Uchime</surname> <given-names>O</given-names></name><name><surname>Herrera</surname> <given-names>R</given-names></name><name><surname>Nguyen</surname> <given-names>V</given-names></name><name><surname>Glen</surname> <given-names>J</given-names></name><name><surname>Lebowitz</surname> <given-names>J</given-names></name><name><surname>Jin</surname> <given-names>AJ</given-names></name><name><surname>Miller</surname> <given-names>LH</given-names></name><name><surname>MacDonald</surname> <given-names>NJ</given-names></name><name><surname>Wu</surname> <given-names>Y</given-names></name><name><surname>Narum</surname> <given-names>DL</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Structure of the <italic>Plasmodium falciparum</italic> circumsporozoite protein, a leading malaria vaccine candidate</article-title><source>Journal of Biological Chemistry</source><volume>284</volume><fpage>26951</fpage><lpage>26963</lpage><pub-id pub-id-type="doi">10.1074/jbc.M109.013706</pub-id><pub-id pub-id-type="pmid">19633296</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Portugal</surname> <given-names>S</given-names></name><name><surname>Tipton</surname> <given-names>CM</given-names></name><name><surname>Sohn</surname> <given-names>H</given-names></name><name><surname>Kone</surname> <given-names>Y</given-names></name><name><surname>Wang</surname> <given-names>J</given-names></name><name><surname>Li</surname> <given-names>S</given-names></name><name><surname>Skinner</surname> <given-names>J</given-names></name><name><surname>Virtaneva</surname> <given-names>K</given-names></name><name><surname>Sturdevant</surname> <given-names>DE</given-names></name><name><surname>Porcella</surname> <given-names>SF</given-names></name><name><surname>Doumbo</surname> <given-names>OK</given-names></name><name><surname>Doumbo</surname> <given-names>S</given-names></name><name><surname>Kayentao</surname> <given-names>K</given-names></name><name><surname>Ongoiba</surname> <given-names>A</given-names></name><name><surname>Traore</surname> <given-names>B</given-names></name><name><surname>Sanz</surname> <given-names>I</given-names></name><name><surname>Pierce</surname> <given-names>SK</given-names></name><name><surname>Crompton</surname> <given-names>PD</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Malaria-associated atypical memory B cells exhibit markedly reduced B cell receptor signaling and effector function</article-title><source>eLife</source><volume>4</volume><elocation-id>e07218</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.07218</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Potocnjak</surname> <given-names>P</given-names></name><name><surname>Yoshida</surname> <given-names>N</given-names></name><name><surname>Nussenzweig</surname> <given-names>RS</given-names></name><name><surname>Nussenzweig</surname> <given-names>V</given-names></name></person-group><year iso-8601-date="1980">1980</year><article-title>Monovalent fragments (Fab) of monoclonal antibodies to a sporozoite surface antigen (Pb44) protect mice against malarial infection</article-title><source>Journal of Experimental Medicine</source><volume>151</volume><fpage>1504</fpage><lpage>1513</lpage><pub-id pub-id-type="doi">10.1084/jem.151.6.1504</pub-id><pub-id pub-id-type="pmid">6991628</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Punjani</surname> <given-names>A</given-names></name><name><surname>Rubinstein</surname> <given-names>JL</given-names></name><name><surname>Fleet</surname> <given-names>DJ</given-names></name><name><surname>Brubaker</surname> <given-names>MA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination</article-title><source>Nature Methods</source><volume>14</volume><fpage>290</fpage><lpage>296</lpage><pub-id pub-id-type="doi">10.1038/nmeth.4169</pub-id><pub-id pub-id-type="pmid">28165473</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Punjani</surname> <given-names>A</given-names></name><name><surname>Fleet</surname> <given-names>DJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>3d variability analysis: directly resolving continuous flexibility and discrete heterogeneity from single particle cryo-EM images</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2020.04.08.032466</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rauscher</surname> <given-names>S</given-names></name><name><surname>Pomès</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Structural disorder and protein elasticity</article-title><source>Advances in Experimental Medicine and Biology</source><volume>725</volume><fpage>159</fpage><lpage>183</lpage><pub-id pub-id-type="doi">10.1007/978-1-4614-0659-4_10</pub-id><pub-id pub-id-type="pmid">22399324</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rauscher</surname> <given-names>S</given-names></name><name><surname>Pomès</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The liquid structure of elastin</article-title><source>eLife</source><volume>6</volume><elocation-id>e26526</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.26526</pub-id><pub-id pub-id-type="pmid">29120326</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rich</surname> <given-names>SM</given-names></name><name><surname>Ferreira</surname> <given-names>MU</given-names></name><name><surname>Ayala</surname> <given-names>FJ</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>The origin of antigenic diversity in <italic>Plasmodium falciparum</italic></article-title><source>Parasitology Today</source><volume>16</volume><fpage>390</fpage><lpage>396</lpage><pub-id pub-id-type="doi">10.1016/S0169-4758(00)01741-5</pub-id><pub-id pub-id-type="pmid">10951599</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Romero</surname> <given-names>P</given-names></name><name><surname>Obradovic</surname> <given-names>Z</given-names></name><name><surname>Li</surname> <given-names>X</given-names></name><name><surname>Garner</surname> <given-names>EC</given-names></name><name><surname>Brown</surname> <given-names>CJ</given-names></name><name><surname>Dunker</surname> <given-names>AK</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Sequence complexity of disordered protein</article-title><source>Proteins: Structure, Function, and Genetics</source><volume>42</volume><fpage>38</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1002/1097-0134(20010101)42:1&lt;38::AID-PROT50&gt;3.0.CO;2-3</pub-id><pub-id pub-id-type="pmid">11093259</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenberg</surname> <given-names>R</given-names></name><name><surname>Wirtz</surname> <given-names>RA</given-names></name><name><surname>Schneider</surname> <given-names>I</given-names></name><name><surname>Burge</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="1990">1990</year><article-title>An estimation of the number of malaria sporozoites ejected by a feeding mosquito</article-title><source>Transactions of the Royal Society of Tropical Medicine and Hygiene</source><volume>84</volume><fpage>209</fpage><lpage>212</lpage><pub-id pub-id-type="doi">10.1016/0035-9203(90)90258-G</pub-id><pub-id pub-id-type="pmid">2202101</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ross</surname> <given-names>LS</given-names></name><name><surname>Fidock</surname> <given-names>DA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Elucidating mechanisms of Drug-Resistant <italic>Plasmodium falciparum</italic></article-title><source>Cell Host &amp; Microbe</source><volume>26</volume><fpage>35</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2019.06.001</pub-id><pub-id pub-id-type="pmid">31295423</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rougé</surname> <given-names>L</given-names></name><name><surname>Chiang</surname> <given-names>N</given-names></name><name><surname>Steffek</surname> <given-names>M</given-names></name><name><surname>Kugel</surname> <given-names>C</given-names></name><name><surname>Croll</surname> <given-names>TI</given-names></name><name><surname>Tam</surname> <given-names>C</given-names></name><name><surname>Estevez</surname> <given-names>A</given-names></name><name><surname>Arthur</surname> <given-names>CP</given-names></name><name><surname>Koth</surname> <given-names>CM</given-names></name><name><surname>Ciferri</surname> <given-names>C</given-names></name><name><surname>Kraft</surname> <given-names>E</given-names></name><name><surname>Payandeh</surname> <given-names>J</given-names></name><name><surname>Nakamura</surname> <given-names>G</given-names></name><name><surname>Koerber</surname> <given-names>JT</given-names></name><name><surname>Rohou</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Structure of CD20 in complex with the therapeutic monoclonal antibody rituximab</article-title><source>Science</source><volume>367</volume><fpage>1224</fpage><lpage>1230</lpage><pub-id pub-id-type="doi">10.1126/science.aaz9356</pub-id><pub-id pub-id-type="pmid">32079680</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>RTS,S Clinical Trials Partnership</collab><name><surname>Agnandji</surname> <given-names>ST</given-names></name><name><surname>Lell</surname> <given-names>B</given-names></name><name><surname>Soulanoudjingar</surname> <given-names>SS</given-names></name><name><surname>Fernandes</surname> <given-names>JF</given-names></name><name><surname>Abossolo</surname> <given-names>BP</given-names></name><name><surname>Conzelmann</surname> <given-names>C</given-names></name><name><surname>Methogo</surname> <given-names>BG</given-names></name><name><surname>Doucka</surname> <given-names>Y</given-names></name><name><surname>Flamen</surname> <given-names>A</given-names></name><name><surname>Mordmüller</surname> <given-names>B</given-names></name><name><surname>Issifou</surname> <given-names>S</given-names></name><name><surname>Kremsner</surname> <given-names>PG</given-names></name><name><surname>Sacarlal</surname> <given-names>J</given-names></name><name><surname>Aide</surname> <given-names>P</given-names></name><name><surname>Lanaspa</surname> <given-names>M</given-names></name><name><surname>Aponte</surname> <given-names>JJ</given-names></name><name><surname>Nhamuave</surname> <given-names>A</given-names></name><name><surname>Quelhas</surname> <given-names>D</given-names></name><name><surname>Bassat</surname> <given-names>Q</given-names></name><name><surname>Mandjate</surname> <given-names>S</given-names></name><name><surname>Macete</surname> <given-names>E</given-names></name><name><surname>Alonso</surname> <given-names>P</given-names></name><name><surname>Abdulla</surname> <given-names>S</given-names></name><name><surname>Salim</surname> <given-names>N</given-names></name><name><surname>Juma</surname> <given-names>O</given-names></name><name><surname>Shomari</surname> <given-names>M</given-names></name><name><surname>Shubis</surname> <given-names>K</given-names></name><name><surname>Machera</surname> <given-names>F</given-names></name><name><surname>Hamad</surname> <given-names>AS</given-names></name><name><surname>Minja</surname> <given-names>R</given-names></name><name><surname>Mtoro</surname> <given-names>A</given-names></name><name><surname>Sykes</surname> <given-names>A</given-names></name><name><surname>Ahmed</surname> <given-names>S</given-names></name><name><surname>Urassa</surname> <given-names>AM</given-names></name><name><surname>Ali</surname> <given-names>AM</given-names></name><name><surname>Mwangoka</surname> <given-names>G</given-names></name><name><surname>Tanner</surname> <given-names>M</given-names></name><name><surname>Tinto</surname> <given-names>H</given-names></name><name><surname>D'Alessandro</surname> <given-names>U</given-names></name><name><surname>Sorgho</surname> <given-names>H</given-names></name><name><surname>Valea</surname> <given-names>I</given-names></name><name><surname>Tahita</surname> <given-names>MC</given-names></name><name><surname>Kaboré</surname> <given-names>W</given-names></name><name><surname>Ouédraogo</surname> <given-names>S</given-names></name><name><surname>Sandrine</surname> <given-names>Y</given-names></name><name><surname>Guiguemdé</surname> <given-names>RT</given-names></name><name><surname>Ouédraogo</surname> <given-names>JB</given-names></name><name><surname>Hamel</surname> <given-names>MJ</given-names></name><name><surname>Kariuki</surname> <given-names>S</given-names></name><name><surname>Odero</surname> <given-names>C</given-names></name><name><surname>Oneko</surname> <given-names>M</given-names></name><name><surname>Otieno</surname> <given-names>K</given-names></name><name><surname>Awino</surname> <given-names>N</given-names></name><name><surname>Omoto</surname> <given-names>J</given-names></name><name><surname>Williamson</surname> <given-names>J</given-names></name><name><surname>Muturi-Kioi</surname> <given-names>V</given-names></name><name><surname>Laserson</surname> <given-names>KF</given-names></name><name><surname>Slutsker</surname> <given-names>L</given-names></name><name><surname>Otieno</surname> <given-names>W</given-names></name><name><surname>Otieno</surname> <given-names>L</given-names></name><name><surname>Nekoye</surname> <given-names>O</given-names></name><name><surname>Gondi</surname> <given-names>S</given-names></name><name><surname>Otieno</surname> <given-names>A</given-names></name><name><surname>Ogutu</surname> <given-names>B</given-names></name><name><surname>Wasuna</surname> <given-names>R</given-names></name><name><surname>Owira</surname> <given-names>V</given-names></name><name><surname>Jones</surname> <given-names>D</given-names></name><name><surname>Onyango</surname> <given-names>AA</given-names></name><name><surname>Njuguna</surname> <given-names>P</given-names></name><name><surname>Chilengi</surname> <given-names>R</given-names></name><name><surname>Akoo</surname> <given-names>P</given-names></name><name><surname>Kerubo</surname> <given-names>C</given-names></name><name><surname>Gitaka</surname> <given-names>J</given-names></name><name><surname>Maingi</surname> <given-names>C</given-names></name><name><surname>Lang</surname> <given-names>T</given-names></name><name><surname>Olotu</surname> <given-names>A</given-names></name><name><surname>Tsofa</surname> <given-names>B</given-names></name><name><surname>Bejon</surname> <given-names>P</given-names></name><name><surname>Peshu</surname> <given-names>N</given-names></name><name><surname>Marsh</surname> <given-names>K</given-names></name><name><surname>Owusu-Agyei</surname> <given-names>S</given-names></name><name><surname>Asante</surname> <given-names>KP</given-names></name><name><surname>Osei-Kwakye</surname> <given-names>K</given-names></name><name><surname>Boahen</surname> <given-names>O</given-names></name><name><surname>Ayamba</surname> <given-names>S</given-names></name><name><surname>Kayan</surname> <given-names>K</given-names></name><name><surname>Owusu-Ofori</surname> <given-names>R</given-names></name><name><surname>Dosoo</surname> <given-names>D</given-names></name><name><surname>Asante</surname> <given-names>I</given-names></name><name><surname>Adjei</surname> <given-names>G</given-names></name><name><surname>Adjei</surname> <given-names>G</given-names></name><name><surname>Chandramohan</surname> <given-names>D</given-names></name><name><surname>Greenwood</surname> <given-names>B</given-names></name><name><surname>Lusingu</surname> <given-names>J</given-names></name><name><surname>Gesase</surname> <given-names>S</given-names></name><name><surname>Malabeja</surname> <given-names>A</given-names></name><name><surname>Abdul</surname> <given-names>O</given-names></name><name><surname>Kilavo</surname> <given-names>H</given-names></name><name><surname>Mahende</surname> <given-names>C</given-names></name><name><surname>Liheluka</surname> <given-names>E</given-names></name><name><surname>Lemnge</surname> <given-names>M</given-names></name><name><surname>Theander</surname> <given-names>T</given-names></name><name><surname>Drakeley</surname> <given-names>C</given-names></name><name><surname>Ansong</surname> <given-names>D</given-names></name><name><surname>Agbenyega</surname> <given-names>T</given-names></name><name><surname>Adjei</surname> <given-names>S</given-names></name><name><surname>Boateng</surname> <given-names>HO</given-names></name><name><surname>Rettig</surname> <given-names>T</given-names></name><name><surname>Bawa</surname> <given-names>J</given-names></name><name><surname>Sylverken</surname> <given-names>J</given-names></name><name><surname>Sambian</surname> <given-names>D</given-names></name><name><surname>Agyekum</surname> <given-names>A</given-names></name><name><surname>Owusu</surname> <given-names>L</given-names></name><name><surname>Martinson</surname> <given-names>F</given-names></name><name><surname>Hoffman</surname> <given-names>I</given-names></name><name><surname>Mvalo</surname> <given-names>T</given-names></name><name><surname>Kamthunzi</surname> <given-names>P</given-names></name><name><surname>Nkomo</surname> <given-names>R</given-names></name><name><surname>Msika</surname> <given-names>A</given-names></name><name><surname>Jumbe</surname> <given-names>A</given-names></name><name><surname>Chome</surname> <given-names>N</given-names></name><name><surname>Nyakuipa</surname> <given-names>D</given-names></name><name><surname>Chintedza</surname> <given-names>J</given-names></name><name><surname>Ballou</surname> <given-names>WR</given-names></name><name><surname>Bruls</surname> <given-names>M</given-names></name><name><surname>Cohen</surname> <given-names>J</given-names></name><name><surname>Guerra</surname> <given-names>Y</given-names></name><name><surname>Jongert</surname> <given-names>E</given-names></name><name><surname>Lapierre</surname> <given-names>D</given-names></name><name><surname>Leach</surname> <given-names>A</given-names></name><name><surname>Lievens</surname> <given-names>M</given-names></name><name><surname>Ofori-Anyinam</surname> <given-names>O</given-names></name><name><surname>Vekemans</surname> <given-names>J</given-names></name><name><surname>Carter</surname> <given-names>T</given-names></name><name><surname>Leboulleux</surname> <given-names>D</given-names></name><name><surname>Loucq</surname> <given-names>C</given-names></name><name><surname>Radford</surname> <given-names>A</given-names></name><name><surname>Savarese</surname> <given-names>B</given-names></name><name><surname>Schellenberg</surname> <given-names>D</given-names></name><name><surname>Sillman</surname> <given-names>M</given-names></name><name><surname>Vansadia</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>First results of phase 3 trial of RTS,S/AS01 malaria vaccine in african children</article-title><source>The New England Journal of Medicine</source><volume>365</volume><fpage>1863</fpage><lpage>1875</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1102287</pub-id><pub-id pub-id-type="pmid">22007715</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>RTS,S Clinical Trials Partnership</collab><name><surname>Agnandji</surname> <given-names>ST</given-names></name><name><surname>Lell</surname> <given-names>B</given-names></name><name><surname>Fernandes</surname> <given-names>JF</given-names></name><name><surname>Abossolo</surname> <given-names>BP</given-names></name><name><surname>Methogo</surname> <given-names>BG</given-names></name><name><surname>Kabwende</surname> <given-names>AL</given-names></name><name><surname>Adegnika</surname> <given-names>AA</given-names></name><name><surname>Mordmüller</surname> <given-names>B</given-names></name><name><surname>Issifou</surname> <given-names>S</given-names></name><name><surname>Kremsner</surname> <given-names>PG</given-names></name><name><surname>Sacarlal</surname> <given-names>J</given-names></name><name><surname>Aide</surname> <given-names>P</given-names></name><name><surname>Lanaspa</surname> <given-names>M</given-names></name><name><surname>Aponte</surname> <given-names>JJ</given-names></name><name><surname>Machevo</surname> <given-names>S</given-names></name><name><surname>Acacio</surname> <given-names>S</given-names></name><name><surname>Bulo</surname> <given-names>H</given-names></name><name><surname>Sigauque</surname> <given-names>B</given-names></name><name><surname>Macete</surname> <given-names>E</given-names></name><name><surname>Alonso</surname> <given-names>P</given-names></name><name><surname>Abdulla</surname> <given-names>S</given-names></name><name><surname>Salim</surname> <given-names>N</given-names></name><name><surname>Minja</surname> <given-names>R</given-names></name><name><surname>Mpina</surname> <given-names>M</given-names></name><name><surname>Ahmed</surname> <given-names>S</given-names></name><name><surname>Ali</surname> <given-names>AM</given-names></name><name><surname>Mtoro</surname> <given-names>AT</given-names></name><name><surname>Hamad</surname> <given-names>AS</given-names></name><name><surname>Mutani</surname> <given-names>P</given-names></name><name><surname>Tanner</surname> <given-names>M</given-names></name><name><surname>Tinto</surname> <given-names>H</given-names></name><name><surname>D'Alessandro</surname> <given-names>U</given-names></name><name><surname>Sorgho</surname> <given-names>H</given-names></name><name><surname>Valea</surname> <given-names>I</given-names></name><name><surname>Bihoun</surname> <given-names>B</given-names></name><name><surname>Guiraud</surname> <given-names>I</given-names></name><name><surname>Kaboré</surname> <given-names>B</given-names></name><name><surname>Sombié</surname> <given-names>O</given-names></name><name><surname>Guiguemdé</surname> <given-names>RT</given-names></name><name><surname>Ouédraogo</surname> <given-names>JB</given-names></name><name><surname>Hamel</surname> <given-names>MJ</given-names></name><name><surname>Kariuki</surname> <given-names>S</given-names></name><name><surname>Oneko</surname> <given-names>M</given-names></name><name><surname>Odero</surname> <given-names>C</given-names></name><name><surname>Otieno</surname> <given-names>K</given-names></name><name><surname>Awino</surname> <given-names>N</given-names></name><name><surname>McMorrow</surname> <given-names>M</given-names></name><name><surname>Muturi-Kioi</surname> <given-names>V</given-names></name><name><surname>Laserson</surname> <given-names>KF</given-names></name><name><surname>Slutsker</surname> <given-names>L</given-names></name><name><surname>Otieno</surname> <given-names>W</given-names></name><name><surname>Otieno</surname> <given-names>L</given-names></name><name><surname>Otsyula</surname> <given-names>N</given-names></name><name><surname>Gondi</surname> <given-names>S</given-names></name><name><surname>Otieno</surname> <given-names>A</given-names></name><name><surname>Owira</surname> <given-names>V</given-names></name><name><surname>Oguk</surname> <given-names>E</given-names></name><name><surname>Odongo</surname> <given-names>G</given-names></name><name><surname>Woods</surname> <given-names>JB</given-names></name><name><surname>Ogutu</surname> <given-names>B</given-names></name><name><surname>Njuguna</surname> <given-names>P</given-names></name><name><surname>Chilengi</surname> <given-names>R</given-names></name><name><surname>Akoo</surname> <given-names>P</given-names></name><name><surname>Kerubo</surname> <given-names>C</given-names></name><name><surname>Maingi</surname> <given-names>C</given-names></name><name><surname>Lang</surname> <given-names>T</given-names></name><name><surname>Olotu</surname> <given-names>A</given-names></name><name><surname>Bejon</surname> <given-names>P</given-names></name><name><surname>Marsh</surname> <given-names>K</given-names></name><name><surname>Mwambingu</surname> <given-names>G</given-names></name><name><surname>Owusu-Agyei</surname> <given-names>S</given-names></name><name><surname>Asante</surname> <given-names>KP</given-names></name><name><surname>Osei-Kwakye</surname> <given-names>K</given-names></name><name><surname>Boahen</surname> <given-names>O</given-names></name><name><surname>Dosoo</surname> <given-names>D</given-names></name><name><surname>Asante</surname> <given-names>I</given-names></name><name><surname>Adjei</surname> <given-names>G</given-names></name><name><surname>Kwara</surname> <given-names>E</given-names></name><name><surname>Chandramohan</surname> <given-names>D</given-names></name><name><surname>Greenwood</surname> <given-names>B</given-names></name><name><surname>Lusingu</surname> <given-names>J</given-names></name><name><surname>Gesase</surname> <given-names>S</given-names></name><name><surname>Malabeja</surname> <given-names>A</given-names></name><name><surname>Abdul</surname> <given-names>O</given-names></name><name><surname>Mahende</surname> <given-names>C</given-names></name><name><surname>Liheluka</surname> <given-names>E</given-names></name><name><surname>Malle</surname> <given-names>L</given-names></name><name><surname>Lemnge</surname> <given-names>M</given-names></name><name><surname>Theander</surname> <given-names>TG</given-names></name><name><surname>Drakeley</surname> <given-names>C</given-names></name><name><surname>Ansong</surname> <given-names>D</given-names></name><name><surname>Agbenyega</surname> <given-names>T</given-names></name><name><surname>Adjei</surname> <given-names>S</given-names></name><name><surname>Boateng</surname> <given-names>HO</given-names></name><name><surname>Rettig</surname> <given-names>T</given-names></name><name><surname>Bawa</surname> <given-names>J</given-names></name><name><surname>Sylverken</surname> <given-names>J</given-names></name><name><surname>Sambian</surname> <given-names>D</given-names></name><name><surname>Sarfo</surname> <given-names>A</given-names></name><name><surname>Agyekum</surname> <given-names>A</given-names></name><name><surname>Martinson</surname> <given-names>F</given-names></name><name><surname>Hoffman</surname> <given-names>I</given-names></name><name><surname>Mvalo</surname> <given-names>T</given-names></name><name><surname>Kamthunzi</surname> <given-names>P</given-names></name><name><surname>Nkomo</surname> <given-names>R</given-names></name><name><surname>Tembo</surname> <given-names>T</given-names></name><name><surname>Tegha</surname> <given-names>G</given-names></name><name><surname>Tsidya</surname> <given-names>M</given-names></name><name><surname>Kilembe</surname> <given-names>J</given-names></name><name><surname>Chawinga</surname> <given-names>C</given-names></name><name><surname>Ballou</surname> <given-names>WR</given-names></name><name><surname>Cohen</surname> <given-names>J</given-names></name><name><surname>Guerra</surname> <given-names>Y</given-names></name><name><surname>Jongert</surname> <given-names>E</given-names></name><name><surname>Lapierre</surname> <given-names>D</given-names></name><name><surname>Leach</surname> <given-names>A</given-names></name><name><surname>Lievens</surname> <given-names>M</given-names></name><name><surname>Ofori-Anyinam</surname> <given-names>O</given-names></name><name><surname>Olivier</surname> <given-names>A</given-names></name><name><surname>Vekemans</surname> <given-names>J</given-names></name><name><surname>Carter</surname> <given-names>T</given-names></name><name><surname>Kaslow</surname> <given-names>D</given-names></name><name><surname>Leboulleux</surname> <given-names>D</given-names></name><name><surname>Loucq</surname> <given-names>C</given-names></name><name><surname>Radford</surname> <given-names>A</given-names></name><name><surname>Savarese</surname> <given-names>B</given-names></name><name><surname>Schellenberg</surname> <given-names>D</given-names></name><name><surname>Sillman</surname> <given-names>M</given-names></name><name><surname>Vansadia</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>A phase 3 trial of RTS,S/AS01 malaria vaccine in african infants</article-title><source>The New England Journal of Medicine</source><volume>367</volume><fpage>2284</fpage><lpage>2295</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1208394</pub-id><pub-id pub-id-type="pmid">23136909</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>RTS,S Clinical Trials Partnership</collab></person-group><year iso-8601-date="2015">2015</year><article-title>Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in africa: final results of a phase 3, individually randomised, controlled trial</article-title><source>The Lancet</source><volume>386</volume><fpage>31</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(15)60721-8</pub-id><pub-id pub-id-type="pmid">25913272</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rubinstein</surname> <given-names>JL</given-names></name><name><surname>Brubaker</surname> <given-names>MA</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Alignment of cryo-EM movies of individual particles by optimization of image translations</article-title><source>Journal of Structural Biology</source><volume>192</volume><fpage>188</fpage><lpage>195</lpage><pub-id pub-id-type="doi">10.1016/j.jsb.2015.08.007</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scally</surname> <given-names>SW</given-names></name><name><surname>Murugan</surname> <given-names>R</given-names></name><name><surname>Bosch</surname> <given-names>A</given-names></name><name><surname>Triller</surname> <given-names>G</given-names></name><name><surname>Costa</surname> <given-names>G</given-names></name><name><surname>Mordmüller</surname> <given-names>B</given-names></name><name><surname>Kremsner</surname> <given-names>PG</given-names></name><name><surname>Sim</surname> <given-names>BKL</given-names></name><name><surname>Hoffman</surname> <given-names>SL</given-names></name><name><surname>Levashina</surname> <given-names>EA</given-names></name><name><surname>Wardemann</surname> <given-names>H</given-names></name><name><surname>Julien</surname> <given-names>JP</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Rare PfCSP C-terminal antibodies induced by live sporozoite vaccination are ineffective against malaria infection</article-title><source>Journal of Experimental Medicine</source><volume>215</volume><fpage>63</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1084/jem.20170869</pub-id><pub-id pub-id-type="pmid">29167197</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scally</surname> <given-names>SW</given-names></name><name><surname>Julien</surname> <given-names>JP</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Peek-Peak-Pique: repeating motifs of subtle variance are targets for potent malaria antibodies</article-title><source>Immunity</source><volume>48</volume><fpage>851</fpage><lpage>854</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2018.04.037</pub-id><pub-id pub-id-type="pmid">29768173</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="software"><person-group person-group-type="author"><collab>Schrodinger LLC</collab></person-group><year iso-8601-date="2015">2015</year><source>The PyMOL Molecular Graphics System</source></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sherrard-Smith</surname> <given-names>E</given-names></name><name><surname>Sala</surname> <given-names>KA</given-names></name><name><surname>Betancourt</surname> <given-names>M</given-names></name><name><surname>Upton</surname> <given-names>LM</given-names></name><name><surname>Angrisano</surname> <given-names>F</given-names></name><name><surname>Morin</surname> <given-names>MJ</given-names></name><name><surname>Ghani</surname> <given-names>AC</given-names></name><name><surname>Churcher</surname> <given-names>TS</given-names></name><name><surname>Blagborough</surname> <given-names>AM</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Synergy in anti-malarial pre-erythrocytic and transmission-blocking antibodies is achieved by reducing parasite density</article-title><source>eLife</source><volume>7</volume><elocation-id>e35213</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.35213</pub-id><pub-id pub-id-type="pmid">29914622</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname> <given-names>RC</given-names></name><name><surname>Vega-Rodríguez</surname> <given-names>J</given-names></name><name><surname>Jacobs-Lorena</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The plasmodium bottleneck: malaria parasite losses in the mosquito vector</article-title><source>Memórias Do Instituto Oswaldo Cruz</source><volume>109</volume><fpage>644</fpage><lpage>661</lpage><pub-id pub-id-type="doi">10.1590/0074-0276130597</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sullivan</surname> <given-names>RT</given-names></name><name><surname>Kim</surname> <given-names>CC</given-names></name><name><surname>Fontana</surname> <given-names>MF</given-names></name><name><surname>Feeney</surname> <given-names>ME</given-names></name><name><surname>Jagannathan</surname> <given-names>P</given-names></name><name><surname>Boyle</surname> <given-names>MJ</given-names></name><name><surname>Drakeley</surname> <given-names>CJ</given-names></name><name><surname>Ssewanyana</surname> <given-names>I</given-names></name><name><surname>Nankya</surname> <given-names>F</given-names></name><name><surname>Mayanja-Kizza</surname> <given-names>H</given-names></name><name><surname>Dorsey</surname> <given-names>G</given-names></name><name><surname>Greenhouse</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>FCRL5 delineates functionally impaired memory B cells associated with <italic>Plasmodium falciparum</italic> exposure</article-title><source>PLOS Pathogens</source><volume>11</volume><elocation-id>e1004894</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1004894</pub-id><pub-id pub-id-type="pmid">25993340</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tahar</surname> <given-names>R</given-names></name><name><surname>Ringwald</surname> <given-names>P</given-names></name><name><surname>Basco</surname> <given-names>LK</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Heterogeneity in the circumsporozoite protein gene of plasmodium malariae isolates from sub-Saharan africa</article-title><source>Molecular and Biochemical Parasitology</source><volume>92</volume><fpage>71</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1016/s0166-6851(97)00226-0</pub-id><pub-id pub-id-type="pmid">9574911</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname> <given-names>JC</given-names></name><name><surname>Tan</surname> <given-names>A</given-names></name><name><surname>Checkley</surname> <given-names>L</given-names></name><name><surname>Honsa</surname> <given-names>CM</given-names></name><name><surname>Ferdig</surname> <given-names>MT</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Variable numbers of tandem repeats in <italic>Plasmodium falciparum</italic> genes</article-title><source>Journal of Molecular Evolution</source><volume>71</volume><fpage>268</fpage><lpage>278</lpage><pub-id pub-id-type="doi">10.1007/s00239-010-9381-8</pub-id><pub-id pub-id-type="pmid">20730584</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname> <given-names>J</given-names></name><name><surname>Sack</surname> <given-names>BK</given-names></name><name><surname>Oyen</surname> <given-names>D</given-names></name><name><surname>Zenklusen</surname> <given-names>I</given-names></name><name><surname>Piccoli</surname> <given-names>L</given-names></name><name><surname>Barbieri</surname> <given-names>S</given-names></name><name><surname>Foglierini</surname> <given-names>M</given-names></name><name><surname>Fregni</surname> <given-names>CS</given-names></name><name><surname>Marcandalli</surname> <given-names>J</given-names></name><name><surname>Jongo</surname> <given-names>S</given-names></name><name><surname>Abdulla</surname> <given-names>S</given-names></name><name><surname>Perez</surname> <given-names>L</given-names></name><name><surname>Corradin</surname> <given-names>G</given-names></name><name><surname>Varani</surname> <given-names>L</given-names></name><name><surname>Sallusto</surname> <given-names>F</given-names></name><name><surname>Sim</surname> <given-names>BKL</given-names></name><name><surname>Hoffman</surname> <given-names>SL</given-names></name><name><surname>Kappe</surname> <given-names>SHI</given-names></name><name><surname>Daubenberger</surname> <given-names>C</given-names></name><name><surname>Wilson</surname> <given-names>IA</given-names></name><name><surname>Lanzavecchia</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>A public antibody lineage that potently inhibits malaria infection through dual binding to the circumsporozoite protein</article-title><source>Nature Medicine</source><volume>24</volume><fpage>401</fpage><lpage>407</lpage><pub-id pub-id-type="doi">10.1038/nm.4513</pub-id><pub-id pub-id-type="pmid">29554084</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tivol</surname> <given-names>WF</given-names></name><name><surname>Briegel</surname> <given-names>A</given-names></name><name><surname>Jensen</surname> <given-names>GJ</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>An improved cryogen for plunge freezing</article-title><source>Microscopy and Microanalysis</source><volume>14</volume><fpage>375</fpage><lpage>379</lpage><pub-id pub-id-type="doi">10.1017/S1431927608080781</pub-id><pub-id pub-id-type="pmid">18793481</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Triller</surname> <given-names>G</given-names></name><name><surname>Scally</surname> <given-names>SW</given-names></name><name><surname>Costa</surname> <given-names>G</given-names></name><name><surname>Pissarev</surname> <given-names>M</given-names></name><name><surname>Kreschel</surname> <given-names>C</given-names></name><name><surname>Bosch</surname> <given-names>A</given-names></name><name><surname>Marois</surname> <given-names>E</given-names></name><name><surname>Sack</surname> <given-names>BK</given-names></name><name><surname>Murugan</surname> <given-names>R</given-names></name><name><surname>Salman</surname> <given-names>AM</given-names></name><name><surname>Janse</surname> <given-names>CJ</given-names></name><name><surname>Khan</surname> <given-names>SM</given-names></name><name><surname>Kappe</surname> <given-names>SHI</given-names></name><name><surname>Adegnika</surname> <given-names>AA</given-names></name><name><surname>Mordmüller</surname> <given-names>B</given-names></name><name><surname>Levashina</surname> <given-names>EA</given-names></name><name><surname>Julien</surname> <given-names>JP</given-names></name><name><surname>Wardemann</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Natural parasite exposure induces protective human Anti-Malarial antibodies</article-title><source>Immunity</source><volume>47</volume><fpage>1197</fpage><lpage>1209</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2017.11.007</pub-id><pub-id pub-id-type="pmid">29195810</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="software"><person-group person-group-type="author"><collab>WHO</collab></person-group><year iso-8601-date="2019">2019</year><source>World Malaria Report 2018</source></element-citation></ref><ref id="bib95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshida</surname> <given-names>N</given-names></name><name><surname>Nussenzweig</surname> <given-names>RS</given-names></name><name><surname>Potocnjak</surname> <given-names>P</given-names></name><name><surname>Nussenzweig</surname> <given-names>V</given-names></name><name><surname>Aikawa</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="1980">1980</year><article-title>Hybridoma produces protective antibodies directed against the sporozoite stage of malaria parasite</article-title><source>Science</source><volume>207</volume><fpage>71</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1126/science.6985745</pub-id><pub-id pub-id-type="pmid">6985745</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zavala</surname> <given-names>F</given-names></name><name><surname>Cochrane</surname> <given-names>AH</given-names></name><name><surname>Nardin</surname> <given-names>EH</given-names></name><name><surname>Nussenzweig</surname> <given-names>RS</given-names></name><name><surname>Nussenzweig</surname> <given-names>V</given-names></name></person-group><year iso-8601-date="1983">1983</year><article-title>Circumsporozoite proteins of malaria parasites contain a single immunodominant region with two or more identical epitopes</article-title><source>Journal of Experimental Medicine</source><volume>157</volume><fpage>1947</fpage><lpage>1957</lpage><pub-id pub-id-type="doi">10.1084/jem.157.6.1947</pub-id><pub-id pub-id-type="pmid">6189951</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.59018.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Faraldo-Gómez</surname><given-names>José D</given-names></name><role>Reviewing Editor</role><aff><institution>National Heart, Lung and Blood Institute, National Institutes of Health</institution><country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Tham</surname><given-names>Wai-Hong</given-names> </name><role>Reviewer</role><aff><institution>University of Melbourne</institution><country>Australia</country></aff></contrib><contrib contrib-type="reviewer"><name><surname>Ward</surname><given-names>Andrew B</given-names></name><role>Reviewer</role><aff><institution>The Scripps Research Institute</institution><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Acceptance summary:</bold></p><p>Reviewers and the Editor were most impressed by this integrative structural biology analysis of the interaction between a monoclonal antibody and a Plasmodium protein target. This thoughtfully designed and well executed study expands our understanding of structural correlates of antibody protection against malaria. It also illustrates how the synergy of X-ray crystallography, single-particle cryo-EM and computer simulations can be uniquely revealing in the study of complex processes in molecular biophysics.</p><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Structural ordering of the <italic>Plasmodium berghei</italic> circumsporozoite protein repeats by inhibitory antibody 3D11&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by José Faraldo-Gómez as the Senior and Reviewing Editor. Reviewers #1 (Wai-Hong Tham) and #3 (Andrew B Ward) have agreed to reveal their identity.</p><p>The reviewers have discussed their reviews with one another. Based on this discussion, and on the individual reviews, we are glad to be able to invite you to submit a revised version of the manuscript that addresses the questions raised by the reviewers and their requests for clarification.</p><p><italic>Reviewer #1:</italic></p><p>The manuscript by Kucharska and Thai et al. describes the mechanism of binding of mouse monoclonal 3D11 to its target antigen <italic>P. berghei</italic> circumsporozoite protein (CSP). CSP is the component of the leading malaria vaccine and previous work had used rodent models to understand the inhibitory nature of antibodies. 3D11 was originally isolated from mice exposed to irradiated <italic>P. berghei</italic> infected mosquitoes. While it has been used widely in many studies, the structural mechanism of binding has not been elucidated, which is the focus of this manuscript. While several studies have now shown how human antibodies bind to PfCSP, it is still important to understand how 3D11 inhibits and how it binds as a comparative study and key piece of knowledge in the development of CSP as a vaccine.</p><p>There is very little to fault in this manuscript. It employs molecular dynamics, X-ray crystallography and cryo-EM – all three complementary techniques to fully visualise how 3D11 binds a single repeat, mixed repeats and on full length PbCSP. If the paper had feature only one or two of these techniques, the mechanism of binding would have been incomplete. The employment of these structural techniques is particularly important for PbCSP, as most inhibitory antibodies bind to the central regions which contain several NANNP, PPPP, PAPP, NPND or NAND motifs so understanding the binding, in particular by cryo-EM is critical.</p><p>My only query is how does the binding change with the use of intact monoclonal antibodies? I do not need to see experimental data for this as I understand it would complicate the structural approaches. Nevertheless, either by vaccination or by antibody-based delivery, intact antibodies are binding. It would be good to hear about how this constrains the binding of repeats and if changes in the IgG backbone can be part of antibody design.</p><p>1) For example, do you observe the same number of 3D11 molecules bound to PbCSP complex to be the same if Fab or intact antibody is used using SEC-MALS?</p><p>2) Would you expect to see differences in cryo-EM if the intact mAb was used?</p><p><italic>Reviewer #2:</italic></p><p>In the present study, Kucharska and colleagues use an integrative structural biology approach to characterize the binding of a monoclonal antibody 3D11 to the Plasmodium circumsporozoite protein (CSP). This thoughtfully designed and executed study is straightforward in its analyses building incrementally on previous data and expands our understanding of structural correlates of antibody protection against malaria. The structural data are particularly impressive and highlight the power of combining X-ray crystallography with single particle cryoEM – the high-resolution X-ray crystal structures with CSP peptides and the 3D11 Fab provide atomic-level details of molecular interactions while the cryoEM structure informs on the overall &quot;structural ordering&quot; of CSP upon antibody binding.</p><p><italic>Reviewer #3:</italic></p><p>Kucharska and Thai et al. use x-ray crystallography and single particle cryoEM examine the molecular principles by which a protective and well-characterized mouse mAb 3D11 engages PbCSP. This work is significant because, to my knowledge, there are no structural studies of antibodies in complex with repeats from Plasmodium species other than <italic>P. falciparum</italic>. Further, the discovery of evolved inter-Fab contacts against PbCSP is highly compelling and suggests this is a phenomenon of CSP independent of specific repeat sequence and mammalian host. Overall, the structural data are convincing and the analysis is well-done. This paper warrants publication in <italic>eLife</italic> as it stands, with minor adjustments outlined below.</p><p>1) From the way it is presented, it is hard to fully appreciate the details of the cryo-EM structure of the 3d11-PbCSP complex, particularly with regards to the inter-Fab contacts. It would be helpful to describe the general locations of these residues within the Fab structure (CDRH/L 1,2,3; FR). This could be compared to the published 311-rsCSP structure in order to understand the structural properties of spiral-inducing antibodies in general. Also see comments on Figure 5 below.</p><p>2) From the binding studies, the authors conclude that 10 or 11 Fabs can bind one molecule of PbCSP. The 2D classes in Figure 4—figure supplement 2B also show what appear to be more than 7 Fabs in a complex. Did the authors use 3D classification to sort out these extended complexes, or are the &quot;trailing&quot; Fabs simply blurred out in the high resolution reconstruction? Did the authors see any reconstructions with a fully occupied CSP? In the Materials and methods, and/or in a supplementary figure, it would be useful to have a few more details of the data processing workflow in Cryosparc, which would inform of if and how the low affinity PPAP/NAND repeats can be occupied simultaneously with the PPPP/NPND repeats.</p><p>3) Figure 5C. It is quite difficult to understand the structural details presented here. This figure would benefit greatly from making at least two panels which present two different views of the interface which focus on different details of the inter-fab contacts. Also, importantly, there is very little structural context outside of the side-chains shown, and the CDR loops to which these residues belong to are unlabeled. As mentioned above, it would be useful to know what general structural features of these antibodies can be utilized to drive high-avidity complex formation on CSP and by consequence stabilize long-range helices.</p><p>4) Figure 4—figure supplement 3 is a little bit confusing. The authors state that the x-ray and cryoEM structures are remarkably similar, which it expected. However, as colored, there are some local changes that are 1.5-2.5 Å RMSD, which is actually fairly large. Presumably this is due to the calculation based on all atom, not backbone. I would expect the larger distances to be localized to side chains rather than backbone, which is colored. It may therefore be better to represent the structure as a cartoon and sticks and color the RMSD based on all the atoms, which would be a more accurate representation. Also, related to point #3 above it would be interesting to know if the sidechains that participate in inter-Fab contacts differ between the EM and x-ray structures.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.59018.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Reviewer #1:</p><p>[…] My only query is how does the binding change with the use of intact monoclonal antibodies? I do not need to see experimental data for this as I understand it would complicate the structural approaches. Nevertheless, either by vaccination or by antibody-based delivery, intact antibodies are binding. It would be good to hear about how this constrains the binding of repeats and if changes in the IgG backbone can be part of antibody design.</p><p>1) For example, do you observe the same number of 3D11 molecules bound to PbCSP complex to be the same if Fab or intact antibody is used using SEC-MALS?</p><p>2) Would you expect to see differences in cryo-EM if the intact mAb was used?</p></disp-quote><p>We thank the reviewer for her positive comments. We agree that the binding of intact monoclonal antibodies to CSP is an interesting and biologically relevant topic of research. However, binding of 3D11 IgG to PbCSP results in the formation of large aggregates due to antibody-mediated crosslinking. This process has previously been observed in the context of the parasite surface and is known as the circumsporozoite precipitation reaction (Yoshida et al., 1980; Potocnjak et al., 1980). Nevertheless, we attempted to biochemically characterize the 3D11 IgG-PbCSP complex using negative-stain electron microscopy and we have now included this data in (Figure 5—figure supplement 2). Based on the 2D analysis, we conclude that 3D11 IgG-PbCSP complexes have a similar architecture to 3D11 Fab-PbCSP complexes; however, the heterogeneity of the 3D11 IgG-PbCSP complexes precluded us from obtaining 3D reconstruction. To describe these results, we have added the following sentences: “To examine whether 3D11 IgG can induce a similar type of spiral conformation of PbCSP as 3D11 Fab, we prepared complexes of 3D11 IgG-PbCSP for negative-stain (ns) EM analysis. […] Our findings are in agreement with a similar analysis previously performed with human 311 Fab and IgG in complex with PfCSP, which also observed the ability of both IgG and Fab to induce a spiral-like conformation in CSP.”</p><disp-quote content-type="editor-comment"><p>Reviewer #3:</p><p>[…]</p><p>1) From the way it is presented, it is hard to fully appreciate the details of the cryo-EM structure of the 3d11-PbCSP complex, particularly with regards to the inter-Fab contacts. It would be helpful to describe the general locations of these residues within the Fab structure (CDRH/L 1,2,3; FR). This could be compared to the published 311-rsCSP structure in order to understand the structural properties of spiral-inducing antibodies in general. Also see comments on Figure 5 below.</p></disp-quote><p>We thank the reviewer for his suggestions. We have introduced additional panels and labels in Figure 5 to provide a more in-depth description of the residues engaging in inter-Fab contacts, and revised the subsection “Contacts between 3D11 Fabs stabilize the PbCSP spiral structure” to describe the positions of these residues of interest relative to the overall Fab structure. We also added the following sentences to the Discussion section: “In human mAbs 311 and 1210, CDR3 regions of both heavy and light chains appear to play a considerable role in forming Fab-Fab contacts. Interestingly, in the case of mAb 3D11, homotypic interactions are mainly mediated by residues localized in HCDR1 and -2, KCDR1, and FR3 regions of both the HC and KC, with little contribution from residues in the CDR3 regions (with the exception of H.Tyr97 in HCDR3 and K.Phe94 in KCDR3).”</p><disp-quote content-type="editor-comment"><p>2) From the binding studies, the authors conclude that 10 or 11 Fabs can bind one molecule of PbCSP. The 2D classes in Figure 4—figure supplement 2B also show what appear to be more than 7 Fabs in a complex. Did the authors use 3D classification to sort out these extended complexes, or are the &quot;trailing&quot; Fabs simply blurred out in the high resolution reconstruction? Did the authors see any reconstructions with a fully occupied CSP? In the Materials and methods, and/or in a supplementary figure, it would be useful to have a few more details of the data processing workflow in Cryosparc, which would inform of if and how the low affinity PPAP/NAND repeats can be occupied simultaneously with the PPPP/NPND repeats.</p></disp-quote><p>We have provided an additional supplementary figure (Figure 4—figure supplement 1) showing the cryoEM data processing workflow in cryoSPARC. Despite extensive 3D classification in cryoSPARC v2 we were unable to obtain 3D classes with varied number of Fabs bound. The final low-pass filtered (20 Å) cryoEM structure indicates ~15 Fabs bound to the PbCSP (Figure 4—figure supplement 2F), although the density of the N- and C-terminal Fabs is very weak. The results of 3D variability analysis in cryoSPARC suggest that the blurring of the distal Fabs is a result of the internal flexibility of the complex (see Figure 4—video 1).We have added the following sentences to describe these observations: “Although the low-pass filtered (20 Å) cryoEM map of the 3D11 Fab-PbCSP complex contains visible density for &gt;10 3D11 Fabs (Figure 4—figure supplement 2F), only the density for the seven central Fabs was strong enough to warrant building a molecular model. Indeed, 3D Variability Analysin in cryoSPARC v2 revealed continuous flexibility at the N- and C-termini of the 3D11 Fab-PbCSP complex (Figure 4—video 1).”</p><disp-quote content-type="editor-comment"><p>3) Figure 5C. It is quite difficult to understand the structural details presented here. This figure would benefit greatly from making at least two panels which present two different views of the interface which focus on different details of the inter-fab contacts. Also, importantly, there is very little structural context outside of the side-chains shown, and the CDR loops to which these residues belong to are unlabeled. As mentioned above, it would be useful to know what general structural features of these antibodies can be utilized to drive high-avidity complex formation on CSP and by consequence stabilize long-range helices.</p></disp-quote><p>We thank the reviewer for his suggestions. We have introduced additional panels and labels to provide a more detailed representation of the complex.</p><disp-quote content-type="editor-comment"><p>4) Figure 4—figure supplement 3 is a little bit confusing. The authors state that the x-ray and cryoEM structures are remarkably similar, which it expected. However, as colored, there are some local changes that are 1.5-2.5 Å RMSD, which is actually fairly large. Presumably this is due to the calculation based on all atom, not backbone. I would expect the larger distances to be localized to side chains rather than backbone, which is colored. It may therefore be better to represent the structure as a cartoon and sticks and color the RMSD based on all the atoms, which would be a more accurate representation. Also, related to point #3 above it would be interesting to know if the sidechains that participate in inter-Fab contacts differ between the EM and x-ray structures.</p></disp-quote><p>We appreciate the concern raised by the reviewer. We have re-calculated the RMSD based on the backbone alone and revised the figure to show this ribbon representation. We have also included additional panels to highlight the all-atom RMSD of residues participating in inter-Fab contacts.</p></body></sub-article></article>